


The Journal of the American Diabetes Association

diabetes

Volume 23 • 1974

INDEX

By Subject and Author



Copyright 1975, by American Diabetes Association, Inc.

DIABETES®

The Journal of the American Diabetes Association

EDITOR, DAVID M. KIPNIS, M.D., *St. Louis*

ASSOCIATE EDITORS: PAUL E. LACY, M.D., *St. Louis* • FRANZ M. MATSCHINSKY, M.D., *St. Louis*

ADVISORY EDITORS: CHARLES H. BEST, M.D., *Toronto* • FRANK N. ALLAN, M.D., *Boston*

ABSTRACTS EDITOR, JOHN A. GALLOWAY, M.D., *Indianapolis* • MANAGING EDITOR, EDWARD W. SANDERSON, *New York*

EDITORIAL BOARD

TERM EXPIRING DECEMBER 1975

DAVID R. CHALLONER, M.D., *Indianapolis*

ALLAN L. DRASH, M.D., *Pittsburgh*

BRYCE L. MUNGER, M.D., *Hershey, Pa.*

HIROMICHI T. NARAHARA, M.D., *Albany*

DANIEL PORTE, JR., M.D., *Seattle*

LILLIAN RECENT, M.D., *Washington, D.C.*

DONALD F. STEINER, M.D., *Chicago*

TERM EXPIRING DECEMBER 1975

SEYMOUR L. ALTERMAN, M.D., *Miami Beach*

FREDERICK G. BERLINGER, M.D., *Chicago*

CHARLES M. CLARK, JR., M.D., *Indianapolis*

N. KATSILAMBROS, M.D., *Athens, Greece*

ROGER L. LERNER, M.D., *New York*

RUSSELL L. POUCHER, M.D., *Whittier, California*

TERM EXPIRING DECEMBER 1976

LESTER BAKER, M.D., *Philadelphia*

REX S. CLEMENTS, JR., M.D., *Birmingham, Alabama*

R. PHILIP EATON, M.D., *Albuquerque*

PHILIP FELIG, M.D., *New Haven*

DONALD B. MARTIN, M.D., *Boston*

GERALD M. REAVEN, M.D., *Palo Alto*

ABSTRACTORS

TERM EXPIRING DECEMBER 1976

IAN M. BURR, M.D., *Nashville*

THAD C. HAGEN, M.D., *Milwaukee*

HUEY G. MCDANIEL, M.D., *Birmingham, Alabama*

RICHARD REYNERTSON, M.D., *Birmingham, Alabama*

PAUL H. SCHREIBMAN, M.D., *Rye, New York*

CHARLES R. SHUMAN, M.D., *Philadelphia*

TERM EXPIRING DECEMBER 1977

JEROME M. FELDMAN, M.D., *Durham*

RONALD K. KALKHOFF, M.D., *Milwaukee*

JOHN H. KARAM, M.D., *San Francisco*

ARTHUR R. LIKE, M.D., *Boston*

THOMAS J. MERIMEE, M.D., *Gainesville, Fla.*

ARTHUR R. RUBENSTEIN, M.D., *Chicago*

GEORGE STEINER, M.D., *Toronto*

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should be addressed in writing to the Secretary of the Association, accompanied by a letter of permission from the senior author.

All signed articles and editorials are the responsibility of the author(s) and

not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the Association. *Manuscript Specifications:* The length of manuscripts (not including special articles or letters) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation will be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing, and if possible, submitted in triplicate together with three copies of figures and photomicrographs.

References should be presented in the style of the following examples: For Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas.

J. Lab. Clin. Med. 7:251-66, Feb. 1922. For Books—Allen, Frederick M.: Studies Concerning Glycosuria and Diabetes. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 1 West 48th Street, New York, New York 10020.

DIABETES: *The Journal of the American Diabetes Association* is published every month by the Association at 1 West 48th Street, New York, New York 10020. © American Diabetes Association, Inc., 1975. All rights reserved under International and Pan-American Copyright Convention.

Professional Members receive the Journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: \$28.00 for one year; \$49.00 for two years; \$70.00 for three years. Individual copies \$2.50. Foreign postage at \$3.00 per year applies to all foreign countries, including Canada, Mexico and other

Subscription and Advertising Information

countries in the Postal Union of the Americas and Spain.


Subscriptions for medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral are \$14.00 per year plus \$3.00 for foreign postage where applicable. Subscriptions in this category may be entered or renewed for only one-year terms.

Correspondence concerning subscriptions should be addressed to the Subscription Department, DIABETES. Checks, money orders and drafts for

subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

Information concerning the microfilm edition of this Journal may be obtained from the offices of University Microfilms, P.O. Box 1346, Ann Arbor, Michigan 48106.

All inquiries about advertising and other business matters should be addressed to the Managing Editor of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertisement and the right to cancel any advertising contract.



SUBJECT INDEX 1974

This index covers all reading matter in Volume 23 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index begins on page 36.

A

ABDOMEN

 pain

 and liver failure and jejunoileal bypass, *921

ACETOACETATE

 and glucose, and adipose tissue metabolism, *561
 and glucose metabolism in skeletal muscle, *347

ACETYLCHOLINE

 and glucose
 and insulin release, *800
 -stimulated insulin secretion
 and extracellular calcium, 494-497

ACID-BASE BALANCES

 and sodium bicarbonate therapy in diabetic ketoacidosis, 406, 407
 and tissue glycogen in normal and diabetic rats, *991

ACID MALTASE deficiency, *923

ACIDOSIS, DIABETIC

 and fetal mortality rates, 302

 and liver glycogen, *991

ACIDOSIS, LACTIC

 and ketoacidosis, *379
 and leukemia, *254
 and phenformin
 and insulin deficiency, *370

ACIDS

 n-hexanedioic and n-octanedioic
 urinary excretion of, 16-20
 hydrochloric
 and immunoreactive secretin and insulin, *796
 nicotinic
 and free fatty acid levels, *860

 and glucagon secretion, *797

 and glucose and insulin release,
 *800

 and glucose turnover and oxidation,
 *333-334

 and hyperlipidemia, 916

 uric

 metabolism, carbohydrates and,
 *993

 xanthurenic

 in streptozotocin diabetic rats, 978

ACROMEGALY

 and diabetic ketoacidosis
 and beta-cell function, *363
 and somatostatin, *989

ADENOCARCINOMA

 of exocrine pancreas
 surgical management, *798
 pancreatic
 in four siblings, *562
 and surgery, *991

ADENOMA

 islet
 and insulin and proinsulin storage,
 *860
 insulin release, *363
 pancreatic beta-cell
 monolayer culture of, *481

ADENOSINE DEAMINASE

 and diabetic ketoacidosis, 127

ADENYLATE CYCLASE

 and insulin inhibition, *481
 in isolated rat fat cells
 and tolbutamide, 51-54

ADIPOCYTES

 and cyclic AMP formation
 and free fatty acids, *347
 insulin binding to
 and age and obesity, *380
 isolated human
 insulin binding to, *354, 565-570

metabolism

 and dibutyryl cyclic 3', 5' AMP,
 *29-39

 protein phosphorylation

 and insulin and epinephrine, *348

 size

 and insulin sensitivity, *354

 and intracellular water space, *370

ADIPOSE TISSUE

 cell size

 and glucose tolerance in obese children, *797

 in obese children, *719

 cellular characteristics

 in lean and obese-hyperglycemic mice, *251

 and fatty acid-enriched diet in rats

 and insulin response to glucose during starvation, 605-609

 lipogenesis

 and adrenalectomy in insulin deficient rats, 143-149

 lipolysis

 in alcoholic ketoacidosis, 437

 lipolysis and glucose metabolism

 and anti-insulin peptides and growth hormones, *863-864

 lipoprotein lipase activity

 and obesity, *367

 and untreated diabetes, *348

 metabolism

 and dibutyryl cyclic 3', 5' AMP,
 *29-39

 and glucose and acetoacetate, *561

 and tolbutamide, 51-54

 perifused

 hormonal effects on, *382

 proliferation and cellularity

 and insulin dosage, *482

 pyruvate metabolism

 and insulin, *154

 triglyceride uptake

 and hypertriglyceridemia, *363

ADRENALECTOMY

 effects on adipose tissue and liver

 lipogenesis

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80

Supplement 1, 337-388

August, 645-724

February, 81-160

May, 389-484

September, 725-804

March, 161-256

June, 485-564

October, 805-868

April, 257-336

July, 565-644

November, 869-932

December, 933-996

SUBJECT INDEX 1974

in insulin deficient rats, 143-149
and exercise-induced glucagon secretion, 82-83, 90-92
and obese hyperglycemic mice, *155-156

ADRENERGIC BLOCKING AGENTS
and epinephrine, 746
and exercise-induced glucagon secretion in rats, 83-92
and glucagon secretion, *860
and streptozotocin resistance in mice, 857

ADRENERGIC SYSTEM
insufficiency
and insulin secretion, *365
and insulin secretion, *862
and alanine, *369
and pancreatic alpha-cell function, *154
and pancreatic glucagon secretion, *797
and plasma catecholamines assays, 1-8

AEROMONAS HYDROPHILA INFECTIONS, *251

AGE
and blood glucose levels, 713-715
and carbohydrate intolerance, *253
and insulin binding to rat adipocytes, *380
and plasma catecholamine assays, 2, 3
and reticuloendothelial system phagocytosis, 219

AKEE
poisoning, 919-920

ALANINE
-induced amino acid alterations, *364
and gluconeogenesis
and insulin, *349
ingestion
and diabetes, *797
and ketone body metabolism
in developing rats, *380
oral administration of
and blood beta-hydroxybutyrate,
and plasma glucose, insulin,
free fatty acids, and growth
hormone in normals and
diabetics, *720
-stimulated insulin and glucagon secretion
and fasting, *481
-stimulated insulin secretion

and adrenergic and cholinergic tone, *369

ALCOHOL
and diabetes control, 440-442
and ketoacidosis, 433-439
and pancreatitis
and glucagon responses to arginine, 257-263

ALDOSE REDUCTASE
purification and immunologic identification technique, 460-467

ALLERGY
to insulin
and purified insulins, *352

ALLOXAN
and insulin secretion
in rat islets perfused in vitro, 517-524
and pancreatic islet permeability, *377
and renal renin activity, 966-967
toxicity
and beta cell studies, *339

ALLOXAN DIABETES
and adrenalectomy, 143
and carbohydrate, lipid and protein metabolism in isolated rat hepatocytes, *384
and carbohydrate metabolism
in isolated fetal rat heart, 662-667
and glucose kinetics during oral glucose tolerance tests, 645-650
and ketone body production
and carnitine esters, 487
and liver glucose metabolism enzymes, 293-301
and liver glutathione-insulin transhydrogenase in rats, 120-121
and neonates and fetuses, 889
and neuropathy, *156
and overt diabetes in offspring, *346
and pancreas transplantation in mice, 183-187
and pancreatic islet tissue glucose and ATP levels, *340
in rats
and cholesterol metabolism, *799
and renin, angiotensin, and norepinephrine study, 962-969

AMERICAN DIABETES ASSOCIATION
annual meetings
Thirty-fourth, 72, 157, 255, 335, 483, 563, 637-638
Thirty-fifth, 801, 929, 995
Committees, editorial boards and state coordinators for the organizational year, 1973-74, 76-79
Diabetes Forecast, 483, 929, 995
available reprints, 158-159
DIABETES subscription rates, 803
Diabetes Week, 564, 644, 803, 866
Established Investigatorships, 563-564, 722-723, 802, 864-865
Lilly Award applications, 641, 723, 802-803, 866
Membership Directory corrections, 931-932
Necrology, 80, 484, 564, 644, 724, 804, 868, 996
new members 159-160, 642-643, 866-867
news of Affiliate Associations, 79, 160, 256, 336, 483-484, 723, 803, 929, 996
News Notes, 79-80, 160, 256, 336, 484, 644, 724, 804, 867-868, 930, 996
Officers and Board of Directors, 1974-1975, 637
Personals, 256, 336, 930
postgraduate courses, 72-75, 157, 158, 255-256, 642, 723, 801, 864, 926-929, 995, 996
Research and Development Awards, 335, 564, 640-641, 722, 801-802, 865-866
Research Grants Program, 75-76
Research Symposia
Twelfth, 335, 483, 563, 642, 721-722, 801, 930
summer camp list, 483

AMERICAN INDIANS
and diabetes
and inter-tribal differences, *385, 841-852

AMINO ACIDS
alanine
and insulin and glucagon secretion, *481
alterations
and alanine infusion studies, *364
branched-chain

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

metabolism, and diabetes, *366
incorporation into protein, *252
insulin responses to
 and small bowel bypass surgery, *364
metabolism
 and obesity, *719-720
 splanchnic, obesity and, *797
removal from bovine insulin
 and immunospecificity and biologic activity changes, 651-656

AMINOPHYLLINE
 and arginine-induced insulin release, 168
pretreatment
 and glucose tolerance and insulin response in partially depancreasized dogs, 429-431

AMPUTATION
 of lower limbs
 and mortality in diabetics, 287-292

AMYLASE
 secretion
 from incubated mouse pancreas, and glucose, insulin and glucagon effects, *858-859

ANGIOPATHY, DIABETIC, *924

ANGIOTENSIN
 response
 and diabetic retinopathy, *368

ANOREXIA
 and liver failure
 and jejunoileal bypass, *921

ANTIBIOTICS
 and gas-forming *Aeromonas hydrophila* infection in diabetics, *251

ANTIBODIES
 to aldose reductase, 465-467
 to cartilage
 and relapsing polychondritis, *482
 to insulin
 and cyclophosphamide, *251
 and diabetes remissions, 622
 and diabetic pregnancy, *859
 and Graves' Disease, *991
 and hypoglycemia, 41-49
 and precipitin reaction study, *480
 and "single-peak" insulin, 276-281

ANTIGENS
 human pancreatic cell-mediated immunity to, 693-697

APOLIPOPROTEIN B
 levels
 and diabetes, 827-833

APOPROTEIN
 composition
 and lipoprotein lipase activity, *364

ARGININE
 alpha cell hypersensitivity to in perfused pancreas of genetically diabetic Chinese hamster, *344
 glucagon responses to
 and chronic pancreatitis, 257-263
 and pancreatectomy, 512-516
 and somatostatin, *356
 and glucose-induced insulin response in diabetics, prediabetics, and healthy subjects, 161-170
 and immunoreactive insulin secretion by perfused rat pancreas, 555
 infusions
 and portal and peripheral vein immunoreactive glucagon, 199-202
 and primary adult myxoedema, *480
 infusion in dogs
 insulin and glucagon regulation of glucose turnover and free fatty acid levels during, 805-814
 and insulin and glucagon secretion and obesity, 657-661
 insulin response to
 in infants of diabetic mothers and normal infants, 815-819
 and pancreatic glucagon responses to somatostatin in normals and diabetics, 876-879
 plasma gastrin responses to
 and chronic pancreatitis, 264-267
 and plasma renin activity, *371
 -stimulated glucagon and insulin secretion
 and clofibrate, *859
 and obesity, *382

ATHEROSCLEROSIS
 and diabetes
 and lipoprotein metabolism, 827, 832

prevention
 and diet, *925

ATROPHY
 optic
 and diabetes, *993

ATROPINE
 and insulin release, *800

AUTOANALYZER
 in serum and urine glucose study, 327-332

B

BABOONS
 and hypovolemic shock
 and insulin release, *635

BACTERIA
Aeromonas hydrophila
 and gas-forming infections, *251
 and phagocytosis and diabetes, 9-15

BASEMENT MEMBRANE
 changes
 and diabetes, *154
 electron microscopy
 and diabetes diagnosis, *562
 layering
 and diabetes, 94-103

BETHANECHOL
 and oral glucose tolerance tests, *341

BIGUANIDES
 and gluconeogenesis inhibition, *369
 hypoglycemic action of, 25-27

BLOOD
 acid-base status
 in juvenile diabetics with ketonuria, 16-20
 beta-hydroxybutyrate
 and alanine, *720, *797
 coagulability
 and stress, *379
 insulin levels
 and liver glutathione-insulin transhydrogenase, 117-124
 ketone body levels
 and lactate, *379

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388	August, 645-724
February, 81-160	May, 389-484	September, 725-804
March, 161-256	June, 485-564	October, 805-868
April, 257-336	July, 565-644	November, 869-932
		December, 933-996

SUBJECT INDEX 1974

ketone responses
 in ketosis-resistant and ketosis-prone diabetes, 270-271
lactate
 and exercise in fasted and fed rats, *368
lactate and alanine
 in small-for-gestational-age infants, *991
leukocyte function
 and diabetes, 9-15
leukocytes
 glutathione-insulin transhydrogenase in, 232-238
lymphocytes
 and phytohemagglutin response, and diabetes, 708-712
portal and peripheral
 and proinsulin, insulin, and C-peptide levels, *350
portal vein
 and immunoreactive insulin and glucagon studies, *380
red cell 2, 3, diphosphoglycerate
 and diabetes and vascular disease, *374
samples
 in alanine infusion study, *364
 in fetal and neonatal rats in streptozotocin-induced diabetes study, 890
 in ketoacidosis study, 405
 in plasma catecholamines study, 2
urea nitrogen
 in alloxan diabetic rats, 965
volume
 in alloxan diabetic rats, 963, 965-966

BLOOD GLUCOSE. See also Blood sugar
 and chlorpropamide, *858
 circadian variations in and glucose loading in normals, 132-136
control
 and continuous intravenous insulin infusion, 732-737
 and deep-sea diving, *381
 and diphenylhydantoin therapy, *798
 and exercise, 82
 in fasted and fed rats, *368
 in infants of diabetic mothers and arginine infusion, 817-819
 insulin, glucagon and growth hormone in primary adult myxoedema, *480
 and insulin releasing polypeptides, 902-904

levels
 and age, 713-715
 and glucagon effects, *635
 and plasma removal rate, *799
lowering
 and fasting triglyceride values, *379
monitoring
 and hypoglycemia diagnosis, *340 and insulinoma surgery, *994
peripheral
 and insulin infusion technique, *990
 and plasma insulin response and glucose infusions in normal dogs, *562
and primary adult myxoedema, *480
 in rat fetuses, 312-313
 and transient plasma insulin elevation, *254
in untreated diabetics, 2
BLOOD PRESSURE
 and adrenergic system, 8
 and diabetes
 and plasma renin activity, 835-840
 and diabetes mortality, 107
 and diabetic neuropathic cachexia, 423
 in plasma catecholamine study, 2, 3
 response to pressor agents
 in alloxan diabetic rats, 964-965
 and vasopressor responsiveness and diabetic retinopathy, *368

BLOOD SUGAR
 in alloxan diabetic, adrenalectomized and pancreatectomized rats, 145-146
levels
 in rats, and phenformin, 25-27
 in small-for-gestational-age infants, *991
 and phenformin, *798, *860
 and phenformin and ethylestrenol, *481
regulation
 and artificial endocrine pancreas, 389-396, 397-404

BODY
 anthropometric measurements and serum glucose levels, *365
 composition and physical training in severe obesity, *634
 weight and diabetes, 107-108
 of infants, and glucose intolerance, *922

weight homeostasis
 in diabetes clinic population, 318-325
weight loss
 and adipose cell size, *797
 and diabetic neuropathic cachexia, 418-423
 and hyperinsulinism, *920
 and intestinal bypass surgery in obesity, *920
 and lipid and carbohydrate metabolism, *799, *861

BOOK AND MANUSCRIPT REVIEWERS, 249-250

BOOK REVIEWS

The Diabetic Foot, edited by Marvin E. Levin and Lawrence W. O'Neal, 333
Glucagon: Molecular Physiology, Clinical and Therapeutic Implications, edited by Pierre J. Lefebvre and Roger H. Unger, 560

BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM

study of relation between insulin-induced hypoglycemia and serum haptoglobin levels, 151-153

BRAIN

biochemical correlates and diabetic ketosis, *383
 cerebral edema and diabetic ketoacidosis, *352 and nonketotic hyperosmolar coma, 525-530
 development and hypoglycemia, *635
 and glucose transport and oxygen consumption in sheep and rabbits, *334

C

CACHEXIA
 and diabetic neuropathy, 418-423

CALCIUM
 and biguanide inhibition of gluconeogenesis, *369
 and cyclic 3'5'-AMP
 and insulin release, *337

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

SUBJECT INDEX 1974

extracellular
and acetylcholine-stimulated insulin secretion, 494-497
and immunoreactive insulin secretion and cobalt studies, *337
and insulin release, *337, 938-941
intrapancreatic injections of
and glucagon secretion in dogs, 55-60

CAPILLARIES
artificial
beta cell culture on, *358
basement membrane
and diabetes, 94-103
of Israeli diabetics, *386

CARBOHYDRATE
absorption
and phenformin, 716-718
dietary
and insulin, glucagon and triglyceride levels in obese subjects, *371
and plasma glucose and insulin responses *925
homeostasis
and obesity, *371
and thalassemia, *992
-induced hyperlipemia
and insulin, glucagon, and insulin-glucagon ratio, *372
intolerance
and hyperinsulinism, *371
and liver cirrhosis, *635
loading
and liver glucose-6-phosphate dehydrogenase and malic enzyme, *990
metabolism
in fetal rat heart, 662-667
and hypertension, *376
and liver glycogen, *991
and methylprednisolone and fasting, *719, *796
and mild viral illness, *482
in normal and diabetic subjects, *370
and prostaglandins, 532-535
in rat hepatocytes, *384
and renin-angiotensin system and catecholamines, 962-969
and weight reduction, *799, *861
oxidation
in normal and diabetic subjects, *370

tolerance
and age, *253
and ethynodiol diacetate, *253-254
tolerance tests
after Coxsackie B4 virus epidemic, *345
in normals and prediabetics, *351
and uric acid metabolism, *993

14-CARBON DIOXIDE
production
by pancreatic islets from hyperglycemic and normoglycemic rats, 469-473

CARCINOMA
differential diagnosis from diabetic neuropathic cachexia, 418
of foregut
clinical findings, *922
gastrointestinal tract
and hypoglycemia, *799
islet-cell
and catecholamine biosynthesis, *363
and streptozotocin, *636
of pancreas
in siblings, *562
and surgical management, *991

CARDIOVASCULAR DISEASE
atherosclerotic
and hyperlipoproteinemia, 832
and diabetes, 105-111
and ouabain-insulin interaction study, *353

CARNITINE ESTERS
and diabetic ketoacidosis, 485-493

CARTILAGE
antibodies to
and relapsing polychondritis, *482

CASE REPORTS
acute necrotizing pancreatitis
and surgery, *925
adenocarcinoma of pancreas in four siblings, *562
alcoholic ketoacidosis, 433-435
cystadenoma of pancreas, *858
diabetes and optic atrophy, *993
diabetic neuropathic cachexia, 418-421
diphenylhydantoin therapy for insulinomas, 192-193
fatal diabetic ketoacidosis and potassium depletion, *381

gas-forming *Aeromonas hydrophila* infection in juvenile diabetic, *251
gastrointestinal tract adenocarcinoma and hypoglycemia, *799
glibenclamide hypersensitivity, 739-742
glucagonoma syndrome, *861
glucose tolerance tests
and gastrinoma and gastrojejunostomy, *993
hyperglycemic nonketotic coma
after renal transplantation, *992
hypoglycemia and autoantibodies to insulin, 41-49
hypoglycemia in compensated chronic renal insufficiency, 982-983
hypoglycemia and Graves' Disease, *991
hypoglycemia induced by sulfonylureas, *634-635
insulin resistance and sulfated insulin therapy, *352
intravascular hemolysis complications, *634
lactic acidosis and leukemia, *254
necrobiosis lipoidica diabetorum and skin grafting, *383
neonatal diabetes, *858
new type of hypoglycemia in newborn infant, *156
nonketotic hyperosmolar coma and frusemide therapy, 247-248
phenformin associated lactic acidosis and insulin deficiency, *370
renal failure as initial manifestation of diabetes, *251
sodium retention in insulin-treated diabetics, 241-242
somatomedin deficiency, *863

CATAGLYKIN
and insulin antagonistic effects of growth hormone, *154

CATECHOLAMINES
binding
and receptor identification, *990
biosynthesis
in pancreatic islet tissue, *363
and cardiac cyclic AMP potentiation and tolbutamide, *366
and hypertension
and diabetes, *376
inactivation
and islets of Langerhans, 754-761
and insulin release, *365
release

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

and hypoglycemia, *341
responses to glucose lowering, *341

CATECHOL-O-METHYLTRANSFERASE
inhibitors, 754-761

CATION(S)
and insulin and glucagon secretion in dogs, 55-60
and insulin secretion, 933-941
-specific ionophores
and insulin secretion, *337

CENTRAL NERVOUS SYSTEM. See also Brain glucoregulator
and autonomic neurotransmitter and inhibitor drugs, *342
and pancreatic insulin secretion, *341

CEREBRAL EDEMA
and diabetic ketoacidosis, *352
and intravascular hemolysis, *634
prevention
in ketoacidosis, *859

CEREBROSPINAL FLUID
pressure
and nonketotic hyperosmolar coma, 525-530
and sodium bicarbonate therapy in diabetic ketoacidosis, 405-411

CHILDREN
and chemical diabetes
and serum proinsulin levels, *382
of diabetic parents
and vectorcardiographic abnormalities, 575-578
with diabetic relatives
and intrahematic glucose metabolism studies, *350
and glucagon response
and dextrose priming, *800
and hypernatremic dehydration and hyperglycemia, *993
and Jamaican vomiting sickness, 919
and ketotic hypoglycemia
and hypoadrenalinemia, *921
obese
and adipose cell size and glucose tolerance, *719
and diet, and adipose cell size and glucose tolerance, *797
and Prader-Willi syndrome
and plasma immunoreactive insulin and growth hormone responses, *156

CHINESE HAMSTERS
genetically diabetic
and alpha cell hypersensitivity to arginine, *344
and insulin and glucagon secretion, *922
and spontaneous diabetes
and kidney ultrastructural changes, *154

CHLORPROMAZINE
and insulin release, *634

CHLORPROPAMIDE
dosage
and diabetic pregnancy, *862
and insulin release
and blood glucose levels, *858

CHOLECYSTOKININ
and intestinal disaccharidase release, *990

CHOLECYSTOSTOMY
and acute necrotizing pancreatitis, *925

CHOLESTEROL
levels
and weight reduction, *861
metabolism
in alloxan-diabetic rats, *799

CHOLESTYRAMINE
and hyperlipidemia, 916

CHOLINERGIC AGENTS
and glucose-induced insulin release, *800
and insulin release, *862

CHOLINERGIC BLOCKADE
and alanine-stimulated insulin secretion, *369
and reactive hypoglycemia, *341

CHONDROCYTES
membrane receptors for nonsuppressible insulin-like activity in, *355

CHROMATOGRAPHY
affinity
and enzyme purification, 537
and insulin receptor purification, *481

and alanine infusion study, *364
gas
and plasma free fatty acid levels in myocardial infarction patients, *923
and plasma phenformin assays, *375
gas-liquid
and urinary excretion of dicarboxylic acids, 16-20
Sephadex G-100
and aldose reductase purification, 462-463
and glucagon immunoreactivity study, *343
and proinsulin synthesis study, *338

CIRCADIAN RHYTHMS
in blood glucose, plasma insulin and growth hormone levels
and glucose loading in normal subjects, 132-136

CIRRHOSIS
and plasma glucagon levels, *635

CLINITEST
evaluation of, 474-479

CLOFIBRATE
and arginine-stimulated glucagon and insulin secretion, *859
and hyperlipidemia, 916, 917

COBALT
and immunoreactive insulin secretion and calcium, *337

COLLAGEN
and glomerular basement membrane and diabetes, *366

COMA
hyperglycemic nonketotic
after renal transplantation, *992
hyperosmolar
and surgery, *634
hypoglycemic
and sulfonamides, *634-635
ketotic hyperosmolar, *561
nonketotic hyperglycemic
and intravascular haemolysis complications, *634
nonketotic hyperosmolar
and cerebral edema and depression of sensorium, 525-530
and frusemide therapy, 247-248
treatment
and small doses of intramuscular insulin, *480

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

and urinary excretion of dicarboxylic acids, 16-20

COMPUTERS
and artificial endocrine pancreas, 389-396, 397-404
and work absenteeism in diabetics study, 957-960

CONCANAVALIN A
and inhibition of insulin receptors interactions, *355

CONGENITAL MALFORMATIONS
and fetal mortality in diabetic pregnancy, 303

CONNELLY, J. RICHARD, 69-71

CORTICOSTEROIDS
and ketoacidosis, *859

CORTISOL
release
and hypoglycemia, *341

COWS
pregnant
and ante- and postpartum insulin secretion, *334

CREATINE PHOSPHOKINASE
and diabetic ketoacidosis, 127
and myocardial infarction detection, *372

CRYOHYPOPHYSECTOMY
and diabetic retinopathy, 698-706

CYCLIC 3',5'-ADENOSINE MONOPHOSPHATE
and adipose tissue metabolism, 51-54
formation by adipocytes
and free fatty acids, *347
and glucagon-insulin ratio, 729-731
and glucagon regulation of glucose turnover
and free fatty acid levels, 813
and gluconeogenesis, *347
and insulin secretion, *337
-like agents
and beta cell stimulation, *385
in rat heart
and tolbutamide, *366
release
and glucose, calcium and ionophore, *337

CYCLOHEXAMIDE
and glucose oxidation, 471, 972

CYCLOPHOSPHAMIDE
inhibition of insulin antibody production
insulin resistance, and experimental immunodiabetes, *251

CYSTADENOMA
of pancreas, *858

CYTOCHALASIN B
and glucose-induced insulin release, *562
in monolayer cell cultures of rat islets of Langerhans, *376

D

DECANOYL CARNITINE
and diabetic ketoacidosis, 485

DEHYDRATION
and hypernatremia
and hyperglycemia, *993

DENERVATION
of rat diaphragm muscle tissue
and ribosome activity, *993

2-DEOXYGLUCOSE
and alloxan
and insulin secretion in isolated rat islets, 520
and immunoreactive insulin secretion by perfused rat pancreas, 556
infusion into hepatic-portal system
and food intake, *636

DEPRESSION
and diabetic neuropathic cachexia, 422-423

DEXTROSE
and glucagon response, *800, *861

DEXTROSTIX REFLECTANCE METER
and hypoglycemia diagnosis, *923

DIABETES INSIPIDUS
and optic atrophy, *993

DIABETES, LIPOATROPHIC
insulin inhibitor of, *385

DIABETES MELLITUS
and acid-base status
and tissue glycogen, *991
adult-onset
and liver enzymes study, 293-298
and alanine administration, *720
and alanine ingestion, *797
and alpha-cell and beta-cell interrelationships, *862-863
and alpha cell hypersensitivity to arginine, *344
and apolipoprotein B levels
and lipoprotein composition, 827-833
and artificial pancreas, 397-404
and basement membrane layering, 94-103
and blood pressure
and plasma renin activity, 835-840
and body weight homeostasis, 318-325
and capillary fragility and basal lamina width, *386
and carbohydrate and lipid metabolism, *370
and cardiovascular disease mortality
and ouabain cardiotoxicity study, *353
and cell-mediated immunity to human pancreas extract, 693-697
chemical
and insulin resistance, 674-677
and proinsulin levels, *382
in Chinese hamsters
and insulin and glucagon secretion, *922
and compensated chronic renal insufficiency
and hypoglycemia, 982-985
control
and alcohol intake, 440-442
and insulin mixtures, *376
and leukocyte function, 9-15
and plasma osmolarity measurement, *561
and psychiatric treatment, *370
and triglyceride levels, *379
and Coxsackie B4 virus epidemic, *345
development
and growth hormone, *71, *251
and obesity, *374
diagnosis
and basement membrane studies, *562
and education, *351
encephalomyocarditis virus-induced, *923
etiology
and viruses, 631-632

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388
February, 81-160	May, 389-484
March, 161-256	June, 485-564
April, 257-336	July, 565-644

SUBJECT INDEX 1974

and fetal pancreas transplantation in rats, *989
 and fibrinolysis
 and phenformin and ethylestrenol, *481
 and free fatty acids response to heparin, *994
 and gas-forming *Aeromonas hydrophila* infection, *251
 genetically potential
 and serum growth hormone studies, *253
 and glomerular basement membrane chemical quantification studies, *366
 and glucagon release, *155
 and gluconeogenesis
 and exercise, *384
 and glucose-induced insulin response and arginine, 161-170
 and growth hormone, *251-252, 783-787
 growth-onset, ketosis-resistant
 and lipolysis, 268-274
 and hemochromatosis, *636
 and heparin
 and free fatty acids, *635
 and high- and low-carbohydrate diets, *994
 and hyperlipidemia
 and diet and drug therapy, 913-917
 and hyperosmolar coma
 and surgery, *634
 and hypertriglyceridemia, *346
 and hypoglycemia
 and autonomic nervous system neuropathy, *342
 and immunogenicity of "single-peak" beef-pork insulin, 276-281
 and impotence, 971-975
 incidence
 and anthropometric measurements, *365
 and insulin
 and continuous intravenous infusion, 732-737
 and fibroblasts, 443-448
 insulin-dependent
 and glucagon responses to arginine and somatostatin, 876-879
 and somatostatin inhibition of pancreatic glucagon responses to arginine, *356
 and insulin-glucagon ratio
 and somatostatin, *356
 and insulin-induced hypoglycemia
 and serum haptoglobin levels, 151-153
 and insulin requirements, *378
 and insulin resistance test, *367
 and insulin secretion
 and pancreatic islet monoamine oxidase, *338
 and insulin therapy
 and sodium retention, 240-246
 insulin-treated
 and endogenous insulin and glucagon, *343
 juvenile
 and diabetic nephropathy, *357
 and family life and personality, *378
 and growth hormone production and metabolic clearance, *254
 and insulin treatment, *374
 and ketoacidosis, and sodium bicarbonate effect on oxygen transport, *924
 with ketonuria, urinary n-hexanedioic and n-octanedioic acid excretion and, 16-20
 long-standing, complications and, *357
 management problems, *386
 and necrobiosis lipoidica diabetorum and skin grafting, *383
 twin studies, *350
 ketosis-resistant
 and hyperglycemia control and plasma insulin responses, *352
 kidney failure as first symptom of, *251
 and kidney size, 788-791
 long-term
 and vascular system study, *482
 and lower limb amputation mortality, 287-292
 and lymphocyte phytohemagglutinin response, 708-712
 and maltose metabolism, *864
 manifestations of, *863
 maternal
 and infant care, *156
 and insulin response to arginine in neonates, 816-819
 maturity-onset
 and chlorpropamide therapy, *858
 and gastric inhibitory polypeptide secretion, *369
 and glipizide therapy, *334
 mild
 and insulin sensitivity, *348
 in monkeys
 and muscle capillary basal lamina thickness, *345
 morbidity and mortality
 in Framingham follow-up study, 105-111
 and myoinositol metabolism, *348
 neonatal, *858
 and nephropathy
 in Pima Indians, 61-68
 and obesity
 and blood coagulability, glucose tolerance and stress, *379
 and hyperinsulinism, *920
 and plasma alpha-cell glucagon, *923
 and optic atrophy, *993
 and oral nutrients after fasting and pancreatic alpha cell function, *373
 and pancreas transplantation, 987-988
 and pancreatic islet ultrastructural changes, *338
 pathogenesis, *154
 and plasma growth hormone
 and exercise, *924-925
 and plasma norepinephrine and epinephrine, 1-8
 prevalence
 in American Indians and other native populations, 841-852
 and hypertriglyceridemia, *351
 in Oklahoma Indian tribes, *385
 and red blood cell 2, 3, diphosphoglycerate, *374
 regulation
 and artificial endocrine pancreas study, 389
 remission
 and insulin secretion studies, 616-622
 and reticuloendothelial system phagocytosis, 218-220
 and serum protein changes
 and microangiopathy, *378
 and sexual dysfunction in males, 306-309
 and skeletal muscle glucose metabolism, *347
 and Somatin release, *154
 sucrose-induced in rats
 and testicular degeneration, *800
 and sulfonylureas, *155
 surveys
 and glucose loading, 189
 and thalassemia, *992
 therapy
 and diet adherence, 669-672
 and tolbutamide-mediated insulin release
 and methysergide maleate, 21-23

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

SUBJECT INDEX 1974

treated and untreated
and fat free, high carbohydrate diet, 138-142
treatment
and body weight, 318-325
and twin studies of insulin release, 684-691
untreated
and adipose tissue lipoprotein lipase, *348
and uremia
and monosaccharides and polyols, *920
virus induced, *345, *381
and work absenteeism study, 957-960

**DIABETIC NEUROPATHIC CA-
CHEXIA, 418-423**

DIAZOXIDE
and amylase secretion from incubated mouse pancreas, *858-859
-induced insulin inhibition
and phentolamine, *365
and insulin release, *365
and insulinomas, 192-197
and streptozotocin diabetes in rats, 282-285
and streptozotocin resistance in mice, 857

DIBUTYRYL CYCLIC 3', 5' AMP
and fat cell metabolism, 29-39
glucose-6-phosphatase response to, *921
and glycogen metabolism in neonatal rat liver, *252

DICHLOROACETATE
and malic enzyme and glucose-6-phosphate dehydrogenase activity, *364

DIET
and adipose cell size and glucose tolerance in obese children, *719, *797
and carbohydrate
and hyperlipemia, *372
and obesity, *371
and diabetes, 669-672
and hypertriglyceridemia, *346
and insulin mixtures, *376
and termination of insulin therapy, *378
fat free, high carbohydrate
and diabetics with fasting hyperglycemia, 138-142

fatty acid-enriched
and beta cell insulin response to glucose in rats, 605-609
high-fat
and glucagon secretion in rats, 869-874
high- and low-carbohydrate
and diabetes, *994
and hypercholesterolemia therapy, 914-915
and hyperlipidemia therapy, 914
and hypertriglyceridemia, 915-916
and insulin resistance study, 675
and intestinal cell DNA synthesis in diabetic rat, 793-794
and moderate alcohol intake
and diabetes control, 440-442
niacin deficient
in streptozotocin diabetic rats, 977-978
and odd-carbon fatty acids
and starvation-induced ketosis in dogs, *925
and plasma glucose and insulin responses in normals, *925
and sucrose-induced diabetes in rats, *800
and sugar consumption
and diabetes development, 851
and ventromedial hypothalamic lesions
and insulin and growth hormone secretion in rats, 203-208

**DI-ISOPROPYLAMMONIUM DI-
CHLOROACETATE**
and streptozotocin diabetes in rats, 179-182

DIPA. See Di-isopropylammonium di-chloroacetate

DIPHENYLHYDANTOIN
and glucose-induced insulin secretion
and insulinoma, 192-197
and glucose tolerance
and hypoglycemia, 679-682
therapy
and endocrine system, *798, *990

DIPHOSPHOGLYCERATE
red blood cell
and diabetes and vascular disease, *374

DISACCHARIDASE
intestinal release
and hormonal stimulation, *990

DNA
content
of normal human pancreas islets of Langerhans, 583-587
replication
and streptozotocin, *373
synthesis
and diet in diabetic rats, 793-794
thymidine incorporation into and nonsuppressible insulin-like activity, *355

DOGS
arginine infusion in
and insulin and glucagon regulation of glucose turnover and free fatty acid levels, 805-814
and carbohydrate metabolism
and methylprednisolone and fasting, *719, *796
depancreatized
and artificial endocrine pancreas, 389-396
depancreatized and insulin-treated
and exercise-induced hypoglycemia, *353
fat absorption studies in, *346
and glipizide and glibenclamide studies, *333
and glucagon and epinephrine infusion calorigenic effects, *863
and glucose loading
homeostatic responses to, *863
and hypoglycemic sulfonamides
and glucagon and insulin secretion, 412-415
insulin and glucagon secretion in
and intrapancreatic potassium and calcium injections, 55-60
and insulin-induced hypoglycemia and ketone body infusion, *859
and insulin release, *365
and insulin secretion
and 5-hydroxytryptamine, *560
and hypothalamic insulin receptors, *341
and intestinal disaccharidase release
and hormones, *990
isolated perfused pancreas
and glucose deprivation and noradrenaline release, *481
and kidney function
and peripheral glucagon levels, *343
normal, methylprednisolone-treated
and alloxan diabetic
and glucose kinetics during oral glucose tolerance tests, 645-650

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388
February, 81-160	May, 389-484
March, 161-256	June, 485-564
April, 257-336	July, 565-644
	August, 645-724
	September, 725-804
	October, 805-868
	November, 869-932
	December, 933-996

SUBJECT INDEX 1974

and pancreas function
and somatostatin, *356

pancreatectomized
and glucagon immunoreactivity, 905-912

and pancreatitis
and glucagon or lactated Ringer solution treatment, *989-990

and partial pancreatectomy
and glucose tolerance and insulin response, 429-431

and plasma insulin response
and blood glucose concentrations, *562

and starvation-induced ketosis
and odd-carbon fatty acids, *925

L-DOPA
conversion to beta cell dopamine, 756-761
and growth hormone assays, *992

DOPAMINE
conversion of L-dopa to, 756-761

DUCKS
and mannoheptulose-induced hyperglucagonemia, *383
and oral hypoglycemic agents
and glucagon and insulin secretion, 412-415

DUODENOSCOPY
and Zollinger-Ellison syndrome, *864

E

ELECTROCARDIOGRAPHY
and potassium replacement therapy in diabetic ketoacidosis, 610-615
and serum enzyme studies, *372

ELECTROPHORESIS
polyacrylamide gel
and glucagon biosynthesis study, *379

EMBRYO
chicken
and membrane receptors for non-suppressible insulin-like activity, *355

EMOTIONS. *See also* Mental health
and epinephrine, 743-746

ENCEPHALOMYOCARDITIS VIRUS
and induced diabetes, *381, *923

and islets of Langerhans lesions in mice, *921-922

ENDOCRINE GLANDS
and diphenylhydantoin therapy, *798, *990

familial multiple adenomatosis and hypergastrinemia, *925

ENTERAMINE
and glucose-induced insulin secretion, *560

ENZYMES
abnormalities
and diabetic ketoacidosis, 126-131
aldose reductase
purification techniques, 460-467
binding
in artificial membrane studies, *994
and birth weight, *991
disaccharidase release
and hormones, *990
glucose-6-phosphate dehydrogenase and malic enzyme
and carbohydrate loading in fasted rats, *990
heart glycogen synthetase D phosphatase
and insulin, *346
and insulin and glucagon degradation, *355, 536-542
insulin-specific protease
and proinsulin assays, 505-511
pancreatic exocrine
and islet cell junctions, *380
phosphofructokinase
and gluconeogenesis, *384

EPINEPHRINE
assays
in untreated diabetics, 1-8
and glucagon secretion, *154
and glucose oxidation, 471, 472
infusion
calorigenic effects, *863
and insulin secretion, *367
and phenformin
and hyperglycemic rats, 26-27
and protein phosphorylation in adipocytes, *348
and serum insulin and free fatty acids
and glucose tolerance, 743-746
-stimulated liver gluconeogenesis and glucose, *347
tests
and ketosis-resistant diabetes, 269-274

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388
February, 81-160	May, 389-484
March, 161-256	June, 485-564
April, 257-336	July, 565-644
	August, 645-724
	September, 725-804
	October, 805-868
	November, 869-932
	December, 933-996

ERYTHROCYTES
and insulin degradation, 233-234

ESKIMOS
and diabetes prevalence, 847, 851

ESOPHAGUS
sphincter pressure
and glucagon, *860

ESTROGEN
and fasting serum triglyceride levels and hyperinsulinemia, *373

ETHANOL
glucose and tolbutamide-mediated insulin response and, 821-825
oxidation in rat liver, *386

ETHYLESTRENOL
and fibrinolysis in diabetics, *481

ETHYNODIOL DIACETATE
treatment
and glucose, insulin, and growth hormone effects, *253-254

EXERCISE
and blood glucose and lactate
in fasted and fed rats, *368
and glucagon secretion in rats, 81-92
and gluconeogenesis
and diabetes, *384
-induced hypoglycemia
in depancreatized insulin-treated dogs, *353
and insulin sensitivity, *720, *798
and lactate
and lipolysis, *796, *989
and metabolism
and obesity, *368
and plasma growth hormone in diabetics, *924-925
and severe obesity, *634

F

FAMILY HISTORY
and genetically potential diabetes
and serum growth hormone studies, *253
and postglucose-loading glycosuria, 190

FASTING. *See also* Starvation
and carbohydrate metabolism
in isolated fetal rat heart, 662-667

SUBJECT INDEX 1974

and methylprednisolone, *719, *796
 and exercise
 and blood glucose and lactate, *368
 and glucose homeostasis, *350
 and insulin secretion
 and alanine, *369
 and perfused pancreatic fragments, 554
 and obesity
 and diurnal changes of plasma glucose, insulin and glucagon, *371
 and oral nutrients
 and pancreatic alpha-cell function, *373
 and plasma glucagon response to oral glucose in diabetic and non-diabetic pregnancy, 771-776
 and plasma norepinephrine and epinephrine
 in untreated diabetes, 1-8
 and renal gluconeogenesis
 and diabetic rats, *373
 response to
 in obob mouse, *377

FAT
 absorption
 enteroinsular signal for, *346

FAT CELLS. See also Adipocytes
 hexose transport, *355
 and insulin receptors, *481
 lipolysis
 and tolbutamide, 51-54
 plasma triglyceride uptake
 and obesity, *367
 and trypsin
 and inhibition of insulin effects on leucine incorporation into protein, *252

FATTY ACIDS
 and beta cell insulin response to glucose in rats, 605-609
 free
 and adipocyte cyclic AMP formation, *347
 and exercise, *796
 and glucagon, insulin and growth hormone secretion, *343
 and glucagon regulation, obesity and, *382
 and glucagon secretion, *860
 and heparin in diabetic patients, *635

FIBROBLASTS
 cultured human insulin action study, *372, 443-448
 membrane receptors for nonsuppressible insulin-like activity in, *355

FRAMINGHAM, MASSACHUSETTS
 diabetes follow-up study in, 105-111

FRAMYCETIN, 741

FRUCTOSE
 growth hormone response to in *Salmonella typhimurium*-infected monkeys, *375
 intolerance
 and liver glycogen phosphorylase, 597-603

FRUCTOSE-1-PHOSPHATE
 and liver phosphorylase, 597-603

FRUCTOSE-U-14-C
 incorporation into rat liver, plasma, and adipose tissue triglycerides, *155

FRUSEMIDE
 and diabetic ketoacidosis, *563
 and nonketotic hyperosmolar coma, 247-248

FUELGEN MICRODENSITOMETRY
 and nuclear DNA content of normal human pancreatic cells, 583-587

G

GALL BLADDER
 function
 and vagotomy and pyloroplasty, *992-993

GANGRENE
 and lower limb amputation
 and mortality in diabetes, 287-292

GASTRIC INHIBITORY POLYPEPTIDE
 secretion
 and maturity-onset diabetes, *369

CASTRIN
 circulating
 glucagon effects on, *480
 pancreatic, *339

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388	August, 645-724
February, 81-160	May, 389-484	September, 725-804
March, 161-256	June, 485-564	October, 805-868
April, 257-336	July, 565-644	November, 869-932
		December, 933-996

SUBJECT INDEX 1974

CASTRINOMA

and gastrojejunostomy
and glucose tolerance tests, *993

GASTROENTERITIS

and hypernatremic dehydration
and hyperglycemia, *993

GASTROINTESTINAL SYSTEM

bypass
and obesity, *920
carbohydrate absorption
and phenformin, 716-718
and diabetic neuropathy, *860
disaccharidase release
and secretin and cholecystokinin, *990
DNA synthesis
and diet, 793-794
duodenal wall tumor
and Zollinger-Ellison syndrome, *864
and enteramine
and glucose-induced insulin secretion, *560
enteroglucagon, *344
and glucagon-induced hypocalcemia
and hypophosphatemia, *989
glucagon-like immunoreactivity
and pancreatectomy study, 512-516
hemorrhage
and pancreatic pseudocyst, *994
and hydrochloric acid and glucose
administration
and circulating immunoreactive secretin and insulin, *796
and intraduodenal administration of hydrochloric acid and glucose
and immunoreactive secretin and insulin, *719
jejunoleal bypass
and liver failure, *921
neoplasms
and hypoglycemia, *799
and phenformin absorption, *798
small bowel bypass for obesity
and insulin response to oral amino acid, *364
sugar absorption
and oral hypoglycemic drugs, 112-115
tumors
clinical studies of, *922

GASTROJEJUNOSTOMY

and glucose tolerance tests, *993

GASTROSTOMY

and acute necrotizing pancreatitis, *925

GLIBENCLAMIDE

action, *333
compared with tolbutamide, *923-924
and glucagon and insulin secretion
in ducks and dogs, 412-415
hypersensitivity reaction
and visceral arteritis, 739-742
and insulin release
and pancreatic islets of normal animals, *560
and intestinal sugar absorption, 112-115

GLIPIZIDE

action, *333
evaluation of, *334

GLISOXEPIDE

compared with tolbutamide, *923-924
and intestinal sugar absorption, 112-115

GLOMERULOSCLEROSIS

intercapillary
and sucrose-induced diabetes, *720
and sucrose-induced diabetes in rats, *800

GLUCAGON

alpha-cell
and diabetes and obesity, *929
and amylase secretion from incubated mouse pancreas, *858-859
binding proteins from liver plasma membranes, *990
biosynthesis
in human pancreatic islets, *379
and circulating gastrin, *480
degrading enzyme
and insulin degradation, 536-542
endogenous
in insulin-treated stable and unstable diabetes, *343
and free fatty acids
and obesity, *382
and glucose turnover and free fatty acid levels
in arginine infusion study, 805-814
and growth hormone release tests, *992
hypoglycemic and insulogenic effects
and blood glucose levels, *635
and hypocalcemia
and hypophosphatemia, *989

immunoassay, *561

immunocytochemical localization in islet cells, *339

immunoreactivity

in depancreatized dogs, 905-912
in globulin fraction of human plasma, *343
and glucose loading and immunoreactive insulin, *380
in portal and peripheral veins after arginine and glucose infusions, 199-202

-induced insulin response

and hypoglycemia diagnosis, *798
and insulinoma diagnosis, *992

-induced proinsulin rise

and insulinomas, *377

infusion

calorigenic effects, *863

-insulin ratio, *862-863
and carbohydrate-induced hyperlipemia, *372

and fasting in ob/ob mice, *377
and hepatic metabolism, 725-731

and somatostatin, *356

-like immunoreactive fraction

in pork gut extract, *344
and lipid metabolism, *344

and lower esophageal sphincter pressure inhibition, *860

and pancreatitis therapy in dogs, *989-990

peripheral levels

and kidney function, *343

and plasma lipids

and hyperlipoproteinemia type, *796

and primary hyperlipoproteinemas, *719

proteolytic degradation of, *355

receptors

identification of, *71, *252

release

and hypoglycemia, *341

and renin release, *371

response

in dextrose-primed neonates, *800, *861

response to arginine

and chronic pancreatitis, 257-263

and somatostatin, *356, 876-879

response to hypoglycemia, *922-923
and autonomic nervous system

neuropathy, *342

and sympathectomy, *342

secretion, *862-863

and adrenergic stimulation, *797

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80

Supplement 1, 337-388

August, 645-724

February, 81-160

May, 389-484

September, 725-804

March, 161-256

June, 485-564

October, 805-868

April, 257-336

July, 565-644

November, 869-932

December, 933-996

SUBJECT INDEX 1974

alanine-stimulated, fasting and, *481
 arginine-stimulated, clofibrate and, *859
 of carcinoid tumors of foregut, *922
 and cyclic AMP, *385
 and epinephrine, *154
 exercise-induced, 81-92
 and high-fat diet in rats, 869-874
 and intrapancreatic potassium and calcium injections, 55-60
 by *in vitro* perfused pancreas of diabetic Chinese hamster, *922
 and obesity, 657-661
 and oral hypoglycemic agents in ducks and dogs, 412-415
 and plasma free fatty acid levels, *343, *797, *860
 by rat fetus, 310-316
 and somatostatin, *374
 tolerance
 and obesity, *383

GLUCAGONOMA SYNDROME, *861

GLUCOCORTICOIDS
 and pancreatic beta cell replication, *720, *798-799

GLUCONEOGENESIS
 and alanine, *720
 epinephrine-stimulated
 and glucose, *347
 and exercise
 and diabetes, *384
 and glucagon secretion
 and high fat diet in rats, 869-874
 and glucose production, *367
 inhibition, *369
 and insulin, *349
 insulin inhibition of, *925
 and phenformin, 25-27
 and phosphofructokinase, *384
 and pneumococcal infection in rat, *369
 renal
 in diabetic rat, *373
 substrate limitation of, 982-985
 substrates
 in small-for-gestational-age infants, *99

GLUCORECEPTORS
 peripheral, *636

GLUCOSE
 and acetoacetate

and adipose tissue metabolism, *561
 administration
 and myotonic dystrophy, *799
 and alloxan
 and insulin secretion in isolated rat islets, 519
 and amylase secretion from incubated mouse pancreas, *858
 catecholamine response to, *341
 and cyclic-3'5'-AMP
 and insulin release, *337
 deprivation
 and noradrenaline release, *481
 enteral administration
 and pancreatectomy, *344
 and epinephrine stimulated gluconeogenesis, *347
 -fatty acid cycle
 and skeletal muscle, *347
 fractional removal rate
 and glucose tolerance tests in normal adults, 454-458
 growth hormone response to
 and *Salmonella typhimurium*-infected monkeys, *375
 in stable and hypoglycemia-prone diabetes, *351
 -induced insulin response, *382
 and arginine, 161-170
 biphasic, *800, *862
 and calcium, *337
 and cytochalasin B, *562
 and diphenylhydantoin treatment of insulinomas, 192-197
 in "essential" and "pancreatic" mild glucose intolerance, *896-901
 by fetal pancreas transplants in rats, *366
 in monolayer cell cultures of rat islets of Langerhans, *376
 and potassium, 956-957
 infusions
 and portal and peripheral vein immunoreactive glucagon, 199-202
 ingestion
 and gastric inhibitory polypeptide release, *369
 racial differences in serum and urine glucose response to, 327-332
 and insulin biosynthesis, *636
 insulin response to
 and pancreatic perfusion technique, 553-554
 and thyroid hormones, *154
 intermittent infusions in pregnant rats and fetal pancreatic beta cell development, *624

intolerance
 "essential" and "pancreatic," 896-901
 and frusemide, 247
 in infants of low birth weight, *922
 intraduodenal administration of
 and immunoreactive secretion and insulin, *719
 intravenous infusion
 and plasma insulin removal rate, *799
 kinetics
 and hypoglycemia of fasting in pregnancy, *342
 levels
 and ketones, *858
 loading
 and glycosuria and hypoglycemia in normals, 189-191
 homeostatic responses to, *863
 in normal subjects, 132-136
 and portal vein and systemic immunoreactive insulin and immunoreactive glucagon, *380
 oxidation
 by pancreatic islets from hyperglycemic and normoglycemic rats, 469-473
 pancreatic beta-cell response to, *155
 in pancreatic islet tissue
 of normal and diabetic rats, *340
 phosphorylation
 and starvation in streptozotocin diabetic rats, 883-885
 plasma glucagon response to
 in diabetic and nondiabetic pregnancy, 771-776
 production
 and gluconeogenesis, *367
 responses
 development in fetal rat pancreas, *375
 in repetitive glucose tolerance tests, 449-452
 semiquantitative urinary assays of, 474-479
 and sorbitol metabolism, *378
 and "staircase" insulin stimulation and obesity, 763-769
 -stimulated immunoreactive insulin and obesity, *920
 -stimulated insulin release
 in nondiabetic twin siblings of diabetic twins, 684-691
 and tolbutamide-mediated insulin response, *372
 and preinfused ethanol, 821-825

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

SUBJECT INDEX 1974

transport
cerebral, *334
and intracellular metabolism, *347

turnover
insulin and glucagon regulation of, 805-814
and methylprednisolone and fasting, *796
during oral glucose tolerance tests in normal, methylprednisolone-treated and alloxan diabetic dogs, 645-650

uptake
of cultured human fibroblasts, 444, 445-448
and growth hormone dosages, 501-502
uptake by insulin
in skeletal muscle, *385

utilization
and biguanides, 25

GLUCOSE METABOLISM
and growth hormone and anti-insulin peptides, *863-864

intrahematic
in children at high risk for diabetes development, *350

and liver enzymes
and adult-onset diabetes, 293-298
in newborn infant, 172-177

and prostaglandins, 532-535

in rat skeletal muscle, and starvation, diabetes, ketone bodies and free fatty acids, 881-888

splanchnic, obesity and, *797

GLUCOSE-6-PHOSPHATE DEHYDROGENASE
and carbohydrate loading in fasted rats, *990

GLUCOSE PHOSPHOTRANSFERASES
in adult onset and alloxan diabetes, 295-297

GLUCOSE TOLERANCE
and diet, 138-142
in obese children, *719, *797
and diphenylhydantoin and hypoglycemia, 679-682

and haemodialysis in patients with kidney failure, *251

and intermittent claudication, *720, *798

intravenous
and disappearance of Staub-

Traugott effect with starvation in obesity, *349

and intravenous ethanol, 822

and mild viral infections, *482

and normal pancreatic islets and tolbutamide and glibenclamide, *560

and obesity
and physical training, *634

and partial pancreatectomy in dogs, 429-431

and prediabetes, *154

and renal failure and haemodialysis, *71

and stress
and obesity, *379

and thalassemia, *992

GLUCOSE TOLERANCE TESTS
and diabetes remissions, 617-621

and ethynodiol diacetate, *253-254

and gastrinoma and gastrojejunostomy, *993

and glucose loading in normal subjects, 189-191

identical oral
insulin and glucose responses to, 449-452

intravenous
and epinephrine, 743-746

and insulin response, fractional glucose removal rate, and insulin resistance in normal adults, 454-458

and mild glucose intolerance, 896-901

and pneumococcal sepsis in monkeys, 544-548

in newborn infants, 172-177

oral
and fasting glucose homeostasis, *350

and intermittent claudication, *798

in normal, methylprednisolone-treated, and alloxan diabetic dogs, 645-650

and primary adult myxoedema, *480

and renal failure, *375

and pancreatitis diagnosis, *635

in partially depancreatized dogs, 429-431

and phenformin action in normals, *798, *860

and phenformin therapy, 624-629

and plasma phenformin assays, *375

serum insulin during
and intravenous ethanol, 822-823

and thyrotoxicosis, *154

and virus-induced diabetes, *345

D-GLUCOSE
14-carbon dioxide production from in hyperglycemic and normoglycemic rats, 469-473

transport, *355

L-GLUCOSE
and alloxan
and insulin secretion in isolated rat islets, 519

GLUCOSE-6-PHOSPHATASE
response to dibutyryl cyclic AMP in human and rat fetal liver cultures, *921

GLUCOSE-U-14-C
incorporation into rat liver, plasma, and adipose tissue triglycerides, *155

GLUTAMATE DEHYDROGENASE
and diabetic ketoacidosis, 127

GLUTAMIC OXALOACETIC TRANS-AMINASE
and myocardial infarction detection, *372

GLUTATHIONE-INSULIN TRANS-HYDROGENASE, *355
in human leukocytes, 232-238

insulin control of, *384

GLYCEROL
release
and somatomedin, 786

GLYCODIAZINE
and intestinal sugar absorption, 112-115

GLYCOGEN
metabolism
and hormones, *252-253

phosphorylase
and fructose intolerance, 597-603

and tolbutamide, 53

in retinal neurons and glial cells in streptozotocin-diabetic rats, 221-231

GLYCOGEN SYNTHETASE D PHOSPHATASE
and insulin, *346, *799

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388	August, 645-724
February, 81-160	May, 389-484	September, 725-804
March, 161-256	June, 485-564	October, 805-868
April, 257-336	July, 565-644	November, 869-932
		December, 933-996

SUBJECT INDEX 1974

GLYCOGENOLYSIS

- and insulin, *349

GLYCOGENOSIS

- type II, in infants, *923

GLYCOLYSIS

- and nonsuppressible insulin-like activity, *355

GLYCOSURIA

- and glucose loading in normal subjects, 189-191

GLYMICINE

- and glucagon and insulin secretion in ducks and dogs, 412-415

GRAVES' DISEASE

- and insulin autoimmunity and hypoglycemia, *991

GROWTH HORMONE

- amino terminal sequence of and insulin potentiation, 943-949
- binding studies, *991
- biosynthesis and insulin, *334
- and diabetes, 783-787
- and kidney size, 790-791
- and diabetes development, *71, *251
- diabetogenic mechanism of, *154
- dosage and metabolic effects, 499-504
- and lipolysis and glucose metabolism of isolated fat cells and adipose tissue, *863-864
- and liver plasma membrane enzymes, phospholipids, and circular dichroism in rats, *156
- and oral glucose loading in normal subjects, 132-136
- production and clearance and juvenile diabetes, *254
- release and hypoglycemia, *341
- tests, *992
- response and Prader-Willi syndrome, *156
- and somatomedin deficiency, *863
- responses to fructose or glucose and *Salmonella typhimurium* infection, *375
- response to oral glucose in stable and hypoglycemia-prone diabetes, *351
- secretion

and plasma free fatty acid levels, *343
and ventromedial hypothalamic lesions in rats, 203-208
secretion and action study, *251-252

GUANASE

- and diabetic ketoacidosis, 127

GUANETHIDINE

- and hypertension and carbohydrate metabolism, *376

GUINEA PIGS

- cyclophosphamide studies in, *251
- insulin antibodies and precipitin reaction studies, *480
- perfused heart and insulin potentiation of ouabain cardiotoxicity, *353

GUNTHER'S DISEASE, *923

H

HAMSTERS. *See also* Chinese hamsters golden

- and virus-induced diabetes, *345
- and viral infections of pancreas, *798, *860

HAPTOGLOBIN

- levels and insulin-induced hypoglycemia, 151-153

HEARING

- and diabetic neuropathy, *358

HEART

- arrhythmias and free fatty acid levels, *923
- femoral-popliteal bypass surgery and serum enzyme studies, *372
- fetal rat and carbohydrate metabolism, fasting and alloxan diabetes, 662-667
- glycogen synthetase D phosphatase and insulin, *346
- muscle insulin receptors in, *354
- and myocardial depolarization abnormalities and diabetes, 572-578
- myocardial infarction and plasma free fatty acid levels, *923

and ouabain cardiotoxicity and insulin, *353

rat and tolbutamide, and contractility and cyclic AMP concentration, *366

HEART DISEASE. *See also* Cardiovascular disease

- atherosclerotic dietary prevention, *925
- and frusemide therapy and nonketotic hyperosmolar coma, 247-248
- and long-standing juvenile diabetes, *357

HEMOCHROMATOSIS

- and diabetes, *636

HEMODIALYSIS

- and changes in glucose tolerance, insulin, serum lipids and lipoproteins, *251
- and glucose tolerance, insulin, serum lipids and lipoproteins, *71
- and renal failure as initial manifestation of diabetes, *251

HEMOLYSIS

- intravascular and nonketotic hyperglycemic diabetic coma, *634

HEMORRHAGE

- gastrointestinal and pancreatic pseudocyst, *994
- pancreatic and glucagon therapy in pancreatitis, *990
- and pancreatitis and near total pancreatectomy, *924

HEPARIN

- and free fatty acid levels and glucagon secretion, *860
- free fatty acid response to and diabetes, *994
- induced free fatty acid elevation and diabetes, *635
- infusion and lipolysis, *348

HEPATECTOMY

- partial and ¹⁴C-triolein labeled plasma disposition in hypothalamic obese rats, *363

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

HEPATOCYTES
ethanol uptake by, *386

HEREDITY
and adenocarcinoma in siblings, *562
and alloxan diabetes, *346
and diabetes, *154, *863
 and dogs, *365
 and optic atrophy, *993
 and vectorcardiographic studies, 575-578
 and viruses, 632
and fructose intolerance
 and liver glycogen phosphorylase, 597-603
and genetically potential diabetes
 and serum growth hormone studies, *253
and insulin release in nondiabetic twin
 siblings of diabetic twins, 684-691
and streptozotocin resistance in mice, 856-857
and twin studies
 and diabetes, *350

HEXOSE
transport
 and insulin, *355

HOMEOSTASIS
and glucose loading, *863

HORMONES
glucoregulatory
 and acute pneumococcal sepsis in
 monkeys, 544-548
and glycogen metabolism, *252-253
and intestinal disaccharidase release, *990
pancreatic
 during perinatal period in rats, 890
and perfused adipose tissue, *382
release
 and hypoglycemia, *341
thyroid
 and insulin secretion, *154

HYALINE MEMBRANE DISEASE
in infants of diabetic mothers, *156

HYDROCHLORIC ACID
insulin and secretin response to, *719
intraduodenal administration
 and immunoreactive secretin and
 insulin, *796

HYDROGEN TEST
and carbohydrate absorption
 and phenformin, 716-718

5-HYDROXYTRYPTAMINE
and insulin secretion, *560

HYPERCHOLESTEROLEMIA
in alloxan diabetic rats, *799
and diet, 914-915
and hyperlipidemia, 913-917
pathogenesis, *796, *989

HYPERGASTRINEMIA
and familial multiple endocrine
 adenomatosis, *925

HYPERGLUCAGONEMIA
and diabetes
 and pancreatitis study, 257-263
 of isolated perfused pancreas of diabetic
 mice, *155
 mannoheptulose-induced, *383
 and sepsis, 547-548

HYPERGLYCEMIA
and arginine-induced insulin release,
 167-168
and beta cell function, *340
control
 and plasma insulin responses in
 ketosis-resistant diabetics,
 *352
and cyclophosphamide, *251
and diabetes
 among American Indian tribes,
 849-850
 and plasma monosaccharides and
 polyols, *920
 and enzyme abnormalities in ketoacidosis,
 129-130
 fasting
 and fat free, high carbohydrate diet,
 138-142
 and hypernatremic dehydration, *993
 and mild diabetes
 and insulin sensitivity, *348
 and neonatal diabetes, *858
 and nonketotic hyperosmolar coma,
 525-531
 and pancreatic islets glucose oxidation
 and insulin secretion in rats,
 469-473
 and prostaglandin study in rats,
 532-535
 in rats
 and phenformin, 25-27
 in very low birth weight infants, *922

HYPERINSULINISM
in genetically obese rats, *253
insulin sensitivity during, *371
and obesity, *797, *920
 and hypertriglyceridemia development,
 *373
transient
 and blood glucose, *254

HYPERLACTATEMIA
and blood ketone bodies, *379

HYPERLIPEMIA
carbohydrate-induced
 and insulin, glucagon and insulin-glucagon ratio, *372

HYPERLIPIDEMIA
and apoprotein composition study,
 *364
classification, 913-918
and diabetes
 diet and drug therapy, 913-918

HYPERLIPOPROTEINEMIA
and diabetes, 827-833
and glucagon effects on plasma lipids,
 *719, *796
and obesity
 and weight reduction, *799, *861

HYPERNATREMIA
and dehydration
 and hyperglycemia, *993

HYPERSENSITIVITY
to glibenclamide, 739-742

HYPERTENSION
essential
 and carbohydrate metabolism, *376

HYPERTRIGLYCERIDEMIA
and adipose tissue triglyceride uptake,
 *363
development
 and hyperinsulinemia and obesity,
 *373
and diabetes control, *379
and diabetes prevalence, *351
and diet, 915-916
etiology
 in insulin deficient rats, *346
 and insulin resistance, *799
and renal failure
 and hemodialysis, *71, *251
and untreated diabetes, *348

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388
February, 81-160	May, 389-484
March, 161-256	June, 485-564
April, 257-336	July, 565-644
	August, 645-724
	September, 725-804
	October, 805-868
	November, 869-932
	December, 933-996

SUBJECT INDEX 1974

HYPOADRENALINEMIA

and insulin hypoglycemia
in hypoglycemic ketotic children, *921

HYPOALANINEMIA

and hypoglycemia, 982-985

HYPOCALCEMIA

glucagon-induced, *989
induced
and insulin secretion, *254

HYPOGLYCEMIA

and alcohol, 440-442
and arginine-induced insulin release, 167-168
and autoantibodies to insulin, 41-49
and cerebral glucose transport, *334
and coma
and sulfonamides, *634-635
and compensated chronic renal insufficiency, 982-985

diagnosis

and blood glucose continuous monitoring, *340
and Dextrostix reflectance meter, *923
and glucagon-induced insulin response, *798
and diphenylhydantoin
and glucose tolerance, 679-682
exercise-induced
in depacreatized insulin-treated dogs, *353
and fasting and pregnancy
and glucose kinetics and insulin, *342

and gastrointestinal tract adenocarcinoma, *799
glucagon response to, *922-923
and sympathectomy, *342

and glucose loading in normal subjects, 189-191
and hormone release, *341

"hyperbaric"
in deep sea divers, *381

infant

and brain development, *635
and insulin autoimmunity

and Graves' Disease, *991

insulin-induced
and ketone body infusion in dogs, *859

and serum haptoglobin level, 151-153
and insulinomas

and diphenylhydantoin and diazoxide, 192-197

and islet-cell carcinoma
and streptozotocin, *636
and Jamaican vomiting sickness, 919

and ketosis
and hypoadrenalinemia in children, *921

neonatal, *156, *253

and nervous system studies, *342

-prone diabetes
and growth hormone response to oral glucose, *351

in rat fetus insulin and glucagon secretion studies, 311, 315-316

reactive
and cholinergic studies, *341
and insulin secretion abnormalities, 589-595

HYPOINSULINEMIA

and mannoheptulose-induced hyperglycemia, *383

HYPOKALEMIA

and electrocardiographic findings, 610-615
and ketoacidosis therapy, *859

HYPOPHOSPHATEMIA

glucagon-induced, *989

HYPOPHYSECTOMY

and diabetic retinopathy, 698-706
and exercise-induced glucagon secretion, 82, 90-92

HYPOTENSION

hemorrhagic
and tolbutamide-induced insulin release, *635
orthostatic
and plasma renin activity, 835-840, 962

HYPOTHALAMUS

insulin-sensitive glucoreceptors
and pancreatic insulin secretion, *341

and somatostatin synthesis, *989

ventromedial lesions
and insulin and growth hormone secretion, 203-208
in obese hyperglycemic mice, *334

I

IMMUNODIABETES

in guinea pigs, *251

IMMUNOLOGY

and diabetes mellitus, 693-697

IMMUNOREACTIVITY

of bovine insulin
and removal of amino acids, 651-656

IMPOTENCE

and diabetes, 306-309, 971-975
and diabetic neuropathic cachexia, 423

INFANTS

of diabetic mothers, *156
and chlorpropamide therapy during pregnancy, *862
and insulin response to arginine, 816-819
and C-peptide immunoreactivity studies, *921

and glucagon response
and dextrose priming, *800
and glycogenesis, type II, *923
low birth weight
and glucose intolerance, *922

neonatal
and dextrose priming and glucagon response, *861
glucose metabolism and insulin secretion study in, 172-177
and neonatal diabetes, *858
and neonatal hypoglycemia, *253
new type of hypoglycemia in, *156
small-for-gestational-age
and increased gluconeogenic substrates, *991

INFECTION. See also Viruses

and diabetes
and reticuloendothelial system phagocytosis study, 218-220
gas-forming *Aeromonas hydrophila* in juvenile diabetic, *251
and leukocyte function in diabetes, 9-15
and lower limb amputation
and mortality in diabetics, 287-292
pneumococcal
and glucose metabolism in monkeys, 544-548
viral
of pancreas, *798, *860

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80

Supplement 1, 337-388

August, 645-724

February, 81-160

May, 389-484

September, 725-804

March, 161-256

June, 485-564

October, 805-868

April, 257-336

July, 565-644

November, 869-932

December, 933-996

SUBJECT INDEX 1974

INSULIN

- action
 - on cultured human fibroblasts, *372, 443-444
- administration
 - and myotonic dystrophy, *799
 - and plasma norepinephrine and epinephrine in untreated diabetes, 1-8
- allergy
 - and purified insulins, *352
 - and alloxan diabetic rats
 - and neuropathy, *156
- and amylase secretion from incubated mouse pancreas, *858-859
- antagonist
 - of lipoatrophic diabetic, *385
- anti-insulin sera reactivity to, *376
- assays
 - and immunologic activity comparisons, *862
- autoantibodies to
 - and hypoglycemia, 41-49
- autoimmunity
 - and Graves' Disease, *991
- and biliary excretion of cholesterol and bile salts, *799
- binding
 - to isolated human adipocytes, *354, 565-570
 - ontogenesis, sex, and pregnancy, *991
- binding and degradation
 - by B and T lymphocytes, *387
 - in perfused rat liver, *354
- binding to rat adipocytes
 - and age and obesity, *380
- biosynthesis, *340
 - in beta-cell tumors of rat pancreas, *345
 - and glucose, *636
- bovine
 - and removal of amino acids, 651-656
- continuous intravenous infusion studies, 732-737
- deficiency
 - and genetic diabetes mellitus, *154
 - and hypertriglyceridemia, *346
 - and phenformin-associated lactic acidosis, *370
- degradation
 - in human leukocytes, 232-238
 - proteolytic, *355
- degrading enzyme
 - and glucagon degradation, 536-542
- dependent diabetes
 - and free fatty acid response to heparin, *994

- and diabetic ketoacidosis, *992
- and diabetic pregnancy
 - and C-peptide immunoreactivity studies in neonates, *921
- dosage
 - and ketoacidosis, 405, *859
 - small, and adipose tissue proliferation and cellularity, *482
- endogenous
 - in insulin-treated stable and unstable diabetes, *343
- exogenous
 - and serum insulin levels, *154-155
 - and fasting hypoglycemia in pregnancy, *342
 - and fat cell hexose transport, *355
 - and feedback control of liver glutathione-insulin transhydrogenase, 117-124
 - glucagon ratio, *862-863
 - and carbohydrate-induced hyperlipemia, *372
 - and fasting in oboe mice, *377
 - and hepatic metabolism, 725-731
 - and protein malnourishment, *796
 - and somatostatin, *356
 - and gluconeogenesis inhibition, *925
 - and glucose and tolbutamide in normal subjects, *372
 - and glucose transport
 - and intracellular metabolism, *347
 - and glucose turnover and free fatty acid levels
 - in arginine infusion study, 805-814
 - glucose uptake by
 - in skeletal muscle, *385
 - and glutathione-insulin transhydrogenase control, *384
 - and glycogenolysis
 - and gluconeogenesis, *349
 - and growth hormone, *154
 - and growth hormone biosynthesis in rat anterior pituitary gland, *334
 - and heart glycogen synthetase D phosphatase, *346
 - hypoglycemia
 - and hypoadrenalinemia, *921
 - immunization
 - and lymphocytic infiltration of pancreatic tissue, *386
 - immunoassays
 - ultra-micro, *921
 - immunocytochemical localization in islet cells, *339
 - immunologic activity
 - comparative assays, *800
 - immunoreactive
 - and calcium, *337
 - and cations, 933-941
 - and glucose loading and immunoreactive glucagon, *360
 - and intraduodenal administration of hydrochloric acid and glucose, *719, *796
 - and Prader-Willi syndrome, *156
 - induced hypoglycemia
 - and glucagon response, *922-923
 - and ketone bodies, *859
 - and serum haptoglobin level, 151-153
 - and intestinal sugar absorption
 - and oral hypoglycemic agents, 115
 - intramuscular small doses
 - and diabetic coma treatment, *480
 - intratopical and intravenous infusion and blood glucose and free fatty acids in peripheral venous blood, *990
 - and leucine incorporation into protein and trypsin, *252
 - and $I^{14}C$ -leucine incorporation into sciatic nerve myelin, *358
 - levels
 - in portal and peripheral blood, *350
 - like activity, nonsuppressible plasma membrane receptors in fibroblasts and chondrocytes for, *355
 - metabolism, *994
 - and mitochondrial metabolism
 - and liver regeneration and atrophy, *799-800
 - moniodination of, *353
 - and myoinositol metabolism, *348
 - and ouabain cardiotoxicity, *353
 - and plasma renin activity
 - in alloxan diabetic rats, 966
 - potentiation
 - and synthetic peptides, 943-949
 - and urine peptide fraction, 950-956
 - precipitin reactions between proinsulin, insulin antibodies and, *480
 - and protein phosphorylation in adipocytes, *348
 - and pyruvate metabolism
 - in rat epididymal adipose tissue, *154
 - radioimmunoassays
 - and confidence limits, *480
 - radioreceptor assay
 - and plasma insulin-like activity measurement, *381
 - receptor-binding affinity assays, *561
 - receptors

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

- January, 1-80
- February, 81-160
- March, 161-256
- April, 257-336

- Supplement 1, 337-388
- May, 389-484
- June, 485-564
- July, 565-644

- August, 645-724
- September, 725-804
- October, 805-868
- November, 869-932
- December, 933-996

SUBJECT INDEX 1974

in autotrophic marine alga, *368
 and concanavalin, *355
 in heart muscle, *354
 hypothalamic, *341
 in liver and fat cell membranes, *481
 in placenta plasma membranes, *990
 in placental tissue, 209-217
 and target cell sensitivity to insulin, *353
 regulation
 and artificial endocrine pancreas, 389-396, 397-404
 release
 and alloxan, *377
 from beta-cell adenoma monolayer cultures, *481
 and beta cell studies, *339
 biphasic, glucose-induced, *862
 and chlorpromazine, *634
 and chlorpropamide, *858
 and diazoxide, 284
 in dogs, *365
 and epinephrine-stimulated glucagon secretion, *154
 and gastric inhibitory polypeptide release, *369
 glucose isomeric specific, *382
 and glucose, calcium, and ionophore, *337
 glucose-induced biphasic, cholinergic agents and, *800
 glucose-induced, cytochalasin B inhibition of, *562
 glucose-induced, in monolayer cell cultures of rat islet of Langerhans, *376
 glucose-stimulated, in nondiabetic twin siblings of diabetic twins, 684-691
 and hypovolemic shock, *635
 and insulin releasing polypeptide infusions in rats, 902-904
 by islet cell adenomas, *363
 and ketones and glucose and free fatty acid, *858
 from normal pancreas islets, tolbutamide and glibenclamide and, *560
 and pancreatic beta-cell ultrastructure, *482
 and phenotolamine, *365
 and tolbutamide and methysergide maleate, 21-23
 and vincristine, *481-482
 resistance
 and adrenalectomy in obese hyper-

glycemic mice, *155-156
 and chemical diabetes, 674-677
 and glucose tolerance tests in normal adults, 454-458
 and glucose turnover, *383
 and hemochromatosis, *636
 and hypertriglyceridemia, *799, *861
 and obesity, *797
 and primary adult myxoedema, *480
 and relapsing polychondritis, *482
 and sulfated insulin therapy, *352
 test, *367
 response
 and fractional glucose removal rate and insulin resistance in normal adults during glucose tolerance tests, 454-458
 glucagon-induced, and insulinoma diagnosis, *992
 glucose-induced, and differential diagnosis of hypoglycemia, *798
 glucose- and tolbutamide mediated, and ethanol preinfusion, 821-825
 and hemodialysis, *71
 and intrahepatic glucose metabolism, *350
 in normal and prediabetic subjects, *351
 and nutritional status, *377
 and partial pancreatectomy in dogs, 429-431
 and phenformin, 624-629
 in repetitive glucose tolerance tests, 449-452
 response to arginine
 in infants of diabetic mothers and normal infants, 816-819
 response to glucose
 and arginine, 161-170
 and fatty acids, 605-609
 by fetal pancreas transplants in rats, *366
 and haemodialysis in patients with renal failure, *251
 in obese children, *797
 response to glucose and tolbutamide in "essential" and "pancreatic" mild glucose intolerance, 896-901
 response to hydrochloric acid, *796
 response to oral amino acids and small bowel bypass surgery, *364
 and ribosome activity, *993
 secretion

acetylcholine-stimulated, extracellular calcium and, 494-497
 and acromegaly with diabetic ketoacidosis, *363
 and aging, *253
 alanine-stimulated, and adrenergic and cholinergic tone, *369
 alanine-stimulated, fasting and, *481
 and alloxan, 517-524
 in American Indian diabetics, 851-852
 arginine-stimulated, clofibrate and, *859
 and catecholamines, 754-761
 and chronic adrenergic insufficiency, *365
 and comparisons of tolbutamide, glibenclamide and glisoxepide, *924
 and cyclic 3'5'-AMP and calcium, *337
 and diabetes in remission, 616-622
 and diphenylhydantoin therapy, *798, *990
 endogenous, and intravenous glucose infusion, *799
 and epinephrine and norepinephrine, *367
 and fetal pancreatic development, *340
 and glipizide, *333
 glucose-induced, and diphenylhydantoin treatment of insulinomas, 192-197
 and glucose loading in normal subjects, 132-136
 and 5-hydroxytryptamine, *560
 and induced hypocalcemia, *254
 and intrapancreatic potassium and calcium injections in dogs, 55-60
 and ionophores, *337
 and methylprednisolone and fasting, *796
 in newborn infant, 172-177
 and obesity, 657-661
 and oral hypoglycemic agents in ducks and dogs, 412-415
 and pancreas fragment perfusion techniques, 550-558
 and pancreas islet monoamine oxidase, *338
 by pancreatic islets from hyperglycemic and normoglycemic rats, 469-473
 and plasma free fatty acid levels, *343

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

SUBJECT INDEX 1974

and potassium, 933-941
in pregnant cows, *334
by rat fetus, 310-316
and reactive hypoglycemia, 589-595
and somatostatin, *374, *989
"staircase" glucose stimulation of, 763-769
and thyroid hormones, *154
and ventromedial hypothalamic lesions in rats, 203-208
by *in vitro* perfused pancreas of diabetic Chinese hamsters, *922

sensitivity
and hyperinsulinism, *371
of large human adipocytes, *354
in mild diabetics, *348
and muscle tissue, *720
and physical training, *798
and starvation and obesity, *349
short- and intermediate-acting mixtures
and diabetes control, *376
"single-peak" beef-pork
immunogenicity study in diabetics, 276-281

storage
in islet adenoma and pancreas, *860
sulfated
and insulin resistance therapy, *352

target cell sensitivity to, *353

therapy
determination of requirement for, *378
and juvenile diabetes, *374
and somatostatin, 876-879

tolerance
and cyclophosphamide, *251

treatment
and cardiovascular disease, 107
and exercise-induced hypoglycemia
in depancreatized dogs, *353
and sodium retention, 240-246

¹²⁵I-INSULIN
binding and degradation studies, *387
binding to rat adipocytes and age and obesity, *380
and placental tissue insulin receptors study, 209-217

INSULIN SPECIFIC PROTEASE, 505-511

INSULINOMAS
diagnosis
and glucagon-induced insulin response, *992

and glucagon stimulation tests, *798
and surgery, *994

and diphenylhydantoin
and glucose-induced insulin secretion, 192-197
and glucagon-induced proinsulin rise, *377

INSULINOPENIA
and pancreatitis, 257-263

INSULINOTROPHIC DRUGS. See Oral hypoglycemic drugs

INTERMITTENT CLAUDICATION
and glucose tolerance, plasma insulin and lipids, *720, *798

IONOPHORES
and cyclic 3'5'-AMP
and insulin release, *337
and insulin secretion, *337

ISLETS OF LANGERHANS
and alcohol, 440
beta cells
and neonatal diabetes, *858
and catecholamines inactivation, 754-761
and cyclophosphamide studies in guinea pigs, *251
DNA content, 583-587
and injection of homogenized islets, 579-582
lesions
in encephalomyocarditis virus-infected mice, *921-922

mouse
and streptozotocin action study, *373

rat
and monolayer cell culture studies, *376

ISOENZYMES
aldose reductase, 460-467

ISOPROTERENOL
and glucagon secretion, *860

J

JAMAICAN VOMITING SICKNESS, 919-920

JAUNDICE
cholestatic

K

KETOACIDOSIS. See also Ketoacidosis, diabetic
alcoholic
clinical studies, 433-439

KETOACIDOSIS, DIABETIC
and acromegaly
and beta cell function, *363
and cerebral edema, *352
fetal
and potassium depletion, *381
and glucagon, *344
juvenile
and sodium bicarbonate effect on oxygen transport, *924
and ketone-body production and oxidation rates, *349
and lactic acidosis, *379
and long-standing juvenile diabetes, *357
management, *562-563, *992
and sodium bicarbonate metabolic effects, 405-411
and octanoylcarnitine, 485-493
and plasma norepinephrine and epinephrine assays, 2-8
and potassium replacement therapy and electrocardiographic monitoring, 610-615
and serum enzyme changes, 126-131
and sodium retention, 240-246
therapy, *859
and small doses of intramuscular insulin, *480

KETO-DIASTIX
evaluation of, 474-479

KETOGENESIS
and carnitine esters, 487-488
and glucagon-insulin ratios, 725-731

KETONE BODIES
and glucose and free fatty acid levels, *858
and glucose metabolism in starved rats, 881-887

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388
February, 81-160	May, 389-484
March, 161-256	June, 485-564
April, 257-336	July, 565-644

August, 645-724	September, 725-804
October, 805-868	November, 869-932
December, 933-996	

SUBJECT INDEX 1974

and glucose utilization in adipose tissue, *561
 infusion
 and insulin-induced hypoglycemia in dogs, *859
 metabolism
 and alanine, *380
 production
 and starvation, *349
 production and oxidation
 and diabetic ketoacidosis, *349
 semiquantitative urinary assays of, 474-479
 utilization
 and alcoholic ketoacidosis, 438

KETONURIA
 and juvenile diabetes
 and urinary n-hexanedioic and n-octanedioic acid excretion, 16-20

KETOSIS
 and diabetes
 among American Indians, 849-850
 and insulin response
 and nutritional status, *377
 and oral hypoglycemic agents, 181
 and hypoglycemia
 and hypoadrenalinemia in children, *921
 -resistant diabetes and plasma insulin responses and hyperglycemia control, *352
 -resistant, growth-onset diabetes and lipolysis, 268-274
 starvation-induced
 and odd-carbon fatty acids, *925

KETOSTIX, 17

KIDNEYS
 aldose reductase
 antiserum to, 467
 and basal lamina layering in diabetics, 96
 chronic failure
 and oral glucose tolerance tests and tolbutamide tests, *375
 and diabetic nephropathy in Pima Indians, 61-68
 failure
 and hemodialysis, *71, *251
 as initial manifestation of diabetes, *251
 function
 and peripheral glucagon levels, *343

and glibenclamide hypersensitivity, 739-742
 glomerular basement membrane
 chemical quantification studies, *366
 glomerular protein synthesis
 in streptozotocin diabetic rats, *357
 glomerulosclerosis
 and pancreatic islet transplantation in diabetic rats, 748-752
 gluconeogenesis
 control in diabetic rat, *373
 insufficiency
 compensated, hypoglycemia and, 982-985
 nephropathy
 and juvenile diabetes, *357
 renin activity
 and alloxan diabetes, 962-969
 and glucagon, *371
 size
 and diabetes, 788-791
 transplantation
 hyperglycemic nonketotic coma
 after, *992
 ultrastructural changes
 and spontaneous diabetes in Chinese hamster, *154

KIMMELSTIEL-WILSON LESION
 and diabetes onset, *251

KREBS CYCLE, 472

L

LACTATE
 and blood ketone bodies
 and urinary ketone body excretion, *379
 and lipolysis inhibition
 and exercise, *796, *989

LACTATED RINGER SOLUTION
 and pancreatitis therapy in dogs, *989-990

LACTIC DEHYDROGENASE
 and myocardial infarction detection, *372

LESIONS
 and diabetes
 and basal lamina layering, 94-103
 glomerular
 and pancreatic islet transplantation, *359, 748-752
 of islets of Langerhans

in encephalomyocarditis virus-infected mice, *921-922
 pancreatic
 and lymphocytic infiltration of pancreatic tissue, *386
 and viruses, 631-632
 skin
 and glucagonoma syndrome, *861
 ventromedial hypothalamic
 and insulin and growth hormone secretion in rats, 203-208
 in obese-hyperglycemic mice, *334

LEUCINE
 and immunoreactive insulin secretion by perfused rat pancreas, 555
 incorporation into protein and trypsin, *252
 metabolism
 in muscles and nerves of diabetic rats, *366

3-H-LEUCINE
 incorporation into protein in cultured human fibroblasts, 444

I-¹⁴-C-LEUCINE
 incorporation into sciatic nerve myelin and insulin, *358

LEUKEMIA
 and lactic acidosis, *254

LEUKOCYTE(S)
 function
 and diabetes control, 9-15
 glutathione-insulin transhydrogenase in, 232-238
 migration test
 and cellular hypersensitivity to human pancreas extract, 693-697

LIPIDS
 metabolism
 and glucagon, *344
 in rat hepatocytes, *384
 and weight reduction, *799, *861

LIPOATROPHY
 and single peak and single component insulin, *374

LIPOGENESIS
 and adrenalectomy in insulin deficient rats, 143-149
 in obese hyperglycemic mice and hyperinsulinemia, *561-562

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388
February, 81-160	May, 389-484
March, 161-256	June, 485-564
April, 257-336	July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

LIPOLYSIS

and dibutyryl cyclic 3', 5' AMP, 37-39
free fatty acid inhibition of, *347
and growth hormone, 503
in isolated fat cells
and adipose tissue and anti-insulin
peptides and growth hor-
mone, *863-864
and perfused adipose tissue, *382
and ketosis-resistant, growth-onset
diabetes, 268-274
and lactate
and exercise, *796, *989
and tolbutamide
in isolated fat cells of rat, 51-54

LIPOPROTEIN

composition
and diabetes, 827-833

LIPOPROTEIN LIPASE

activity
and obesity, *367
in adipose tissue
and untreated diabetes, *348
and apoprotein composition, *364
and diabetes control
and postprandial triglyceride val-
ues, *379

LIVER

biopsies
and jejunoleal bypass surgery, *921
cirrhosis
and plasma glucagon levels, *635
and enzyme abnormalities
in diabetic ketoacidosis, 129
enzymes
and adult-onset diabetes, 293-298
fatty changes and glycogen depletion
and Jamaican vomiting sickness, 919
and glibenclamide hypersensitivity
reaction, 739-742
glucagon receptors, *71
gluconeogenesis
and glucagon secretion, in rats with
high-fat diet,
869-874
glucose inhibition of epinephrine
stimulation of, *347
insulin inhibition of, *925
and pneumococcal infection in rat,
*369
glucose-6-phosphate dehydrogenase
and malic enzyme
and carbohydrate loading in fasted
rats, *990

glucose production
and insulin, *349
glutathione-insulin transhydrogenase
insulin control of, 117-125
glycogen
and fasting, *796
glycogen phosphorylase
and fructose intolerance, 597-603
human and rat fetal cultures
and glucose-6-phosphatase response
to dibutyryl cyclic AMP, *921
and hypercholesterolemia, *989
and hypoglycemic action of bi-
guanides, 25-27
and immunoreactive insulin and
glucagon, *380
insulin binding
and fasted mice, *377
and insulin, growth hormone, and
prolactin-binding studies,
*991

insulin and proinsulin, *994
and insulin receptors, *481
insulin resistance
and obesity, *797
and jejunoleal bypass surgery for
obesity, *921
ketogenesis
and alcoholic ketoacidosis, 437-438
and decanoylcarnitine, 485
and glucagon, *344
ketone bodies
and nutritional status, *377
lipogenesis
and adrenalectomy in insulin defi-
cient rats, 143-149
malic enzymes and glucose-6-phos-
phate dehydrogenase
and dichloracetate, *364
metabolism
and glucagon, *344
and glucagon-insulin ratios, 725-731
neonatal rat
and hormonal regulation of glycogen
metabolism, *252-253
perfused rat
insulin binding and degradation in,
*354
plasma membranes
and glucagon binding, *252, *990
and growth hormone, *156
rat
and ethanol oxidation, *386
regeneration and atrophy
and insulin and mitochondrial
metabolism, *799-800

LYMPHOCYTES

and infiltration of pancreatic tissue,
*386
normal human B and T
and insulin binding and degrada-
tion, *387
transformation response to phyto-
hemagglutinin
and diabetes, 708-712

M

MALIC ENZYME

and carbohydrate loading in fasted
rats, *990

MALNUTRITION

protein
and plasma insulin and glucagon,
*719

MALTOSE

metabolism
in diabetics and normals, *864

MANNITOL

and cerebral edema, *859

MANNOHEPTULOSE

and alloxan
and insulin secretion in isolated rat
islets, 520-521
and immunoreactive insulin secretion
by perfused rat pancreas, 555
-induced hyperglucagonemia, *383

MASS SPECTROMETRY

and urinary studies in juvenile diabet-
ics with ketonuria, 16-20

MELANESIANS

and diabetes prevalence, 848

MENTAL HEALTH

and diabetes control, *370
and juvenile diabetes, *378

METABOLISM

adipocyte ^{32}P -phosphopeptide
and insulin and epinephrine, *348
adipose tissue
and glucose and acetoacetate, *561
and perfusion, *382
amino acid
and obesity, *719-720

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

and calorogenic effects of glucagon and epinephrine infusion in dogs, *863
carbohydrate
 in fetal rat heart, 662-667
 and methylprednisolone and fasting, *719, *796
 and mild viral illness, *482
 and pregnancy, 771-776
carbohydrate and lipid
 and diabetes, *370
carbohydrate, lipid and protein
 in isolated hepatocytes, *384
cholesterol
 in alloxan-diabetic rats, *799
 and compensated chronic renal insufficiency,
 and hypoglycemia, 982-985
 of cultured human fibroblasts
 and insulin, 443-448
 and diphenylhydantoin therapy, *798
 endogenous proinsulin
 and insulin, *994
ethanol
 in rat liver, *386
 and exercise
 and obesity, *368
fat cell
 and dibutyryl cyclic 3', 5' AMP, 29-39
glucose
 in newborn infant, 172-177
 and nicotinic acid, *333-334
 and prostaglandins, 532-535
 in rat skeletal muscle, 881-887
 in skeletal muscle, *347
glycogen
 and hormones, *252-253
growth hormone
 in juvenile diabetics, *254
 and growth hormone effects, 499-504
intracellular
 and glucose transport, *347
 and islet cell adenomas, *363
 of isolated fat cells and adipose tissue
 and anti-insulin peptides and
 growth hormones, *863-864
ketone body
 and alanine, *380
 and diabetic ketoacidosis, *349
leucine
 in muscle and nerves of diabetic rats, *366
lipid
 and glucagon, *344
 lipid and carbohydrate
 and weight reduction, *799, *861

lipoprotein
 and diabetes, 827-833
liver
 and glucagon-insulin ratios, 725-731
 and hypercholesterolemia, *989
maltose
 in diabetics and normals, *864
mitochondrial
 and insulin, *799-800
muscle
 and intermittent claudication, *798
myoinositol
 and diabetes, *348
 and progestogens, *253-254
protein
 and diabetic microangiopathy, *578
pyruvate
 and insulin, *154
 and sodium bicarbonate therapy in ketoacidosis, 405-411
sorbitol
 in isolated pancreatic islets, *378
triglyceride
 and clofibrate, *859
 splanchnic glucose and amino acid and obesity, *797
tryptophan-niacin
 and streptozotocin diabetic rats, 977-980
uric acid
 and carbohydrates, *993

METABOLITES
brain
 in ketotic and non-ketotic diabetic mice, *383

METHACHOLINE
 and glucose
 and insulin release, *800

3-O-METHYL-GLUCOSE
 and alloxan
 and insulin secretion in isolated rat islets, 519
 uptake, *355

N¹-METHYLNICOTINAMIDE
 and tryptophan administration in streptozotocin diabetic rats, 977-980

METHYLPREDNISOLONE
 and carbohydrate metabolism
 and fasting, *719, *796
 and glucose kinetics during oral glucose tolerance tests, 645-650

METHYSERGIDE MALEATE
 and potentiation of tolbutamide-mediated insulin release
 and adult-onset diabetes, 21-23

MICE
 and encephalomyocarditis virus-induced diabetes, *921-922, *923
 genetically diabetic KK
 and streptozotocin resistance, 856-857
 islets of Langerhans
 and streptozotocin action, *373
 ketotic and non-ketotic diabetic
 and brain biochemical correlates, *383
 obese-hyperglycemic
 and adrenalectomy, *155-156
 and insulin binding studies, *354
 and lipogenesis, *561-562
 and ventromedial hypothalamic lesions, *334
 obese-hyperglycemic and lean adipose tissue studies in, *251
 obo
 and fasting, *377
 and pancreas transplantation and recovery from experimental diabetes, 183-187

MICROANGIOPATHY, DIABETIC,
 *482
 and serum protein changes, *378

MICRONESIANS
 and diabetes prevalence, 848

MICROSCOPY
 and basal lamina study in diabetics, 94-103
 of corpora cavernosa nervous fibers in impotent diabetic males, 973-975
 electron
 and glucagonoma syndrome, *861
 and hyperlipidemia and diabetes diagnosis, *562
 and immunocytochemical localization of insulin and glucagon, *339
 of islet and acinar cells, and virus-induced diabetes, *345
 and pancreatic islets ultrastructural alterations in diabetes, *338
 and retinal glycogen accumulation in diabetic rats, 221-231

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

SUBJECT INDEX 1974

of glomerulus from diabetic rats
and pancreatic tissue transplantation, 750-752

islet cell
and injection of homogenized islets in rats, 580-582

light and electron
and glucocorticoid-induced pancreatic beta cell replication, *720

and glucocorticoid-induced pancreatic beta cell replication in monkeys, *798-799

of pancreatic islets of genetically obese rats, *253

and viral infection of pancreas, *798

MITOCHONDRIA
calcium fluxes
and phenethylbiguanide, *369

metabolism
and insulin, *799-800

MONKEYS
and glucocorticoid-induced pancreatic beta-cell replication, *720, *798-799

Macaca nigra
muscle capillary basal lamina thickness in normal and diabetic, *345

pregnant
and placental transfer of streptozotocin, 777-782

and *Salmonella typhimurium* infection and growth hormone responses to fructose and glucose, *375

¹²⁵I-MONOIOODOINSULIN
preparation and biological properties, *353

MONOSACCHARIDES
and immunoreactive insulin secretion by perfused rat pancreas, 555

MORTALITY
and acute necrotizing pancreatitis and surgery, *925

and amputation for lower limb infection or gangrene in diabetics, 287-292

and cardiovascular disease and diabetes, *353

in diabetes Framingham study, 105-111

and diabetic ketoacidosis

and enzyme abnormalities, 127-128
and potassium depletion, *381

and diabetic ketoacidosis management, *562-563

and diabetic nephropathy, *357

and diabetic pregnancy
and chlorpropamide therapy, *862

fetal perinatal
in diabetic pregnancy, 302-305

and glibenclamide hypersensitivity, 739-742

and hemorrhagic pancreatitis
and near total pancreatectomy, *924

and hypophsectomy, 702

and infants of diabetic mothers, *156

and jejunoleal bypass for obesity and liver failure, *921

and pancreas biopsy, *991

and surgery
and hyperosmolar coma, *634
and treatment of pancreatitis, *922

MUSCLE
atrophy
and diabetic neuropathic cachexia, 419-421

basal lamina capillary thickness in diabetic monkeys, *345

dystrophy
and glycogen synthase system, *799

enzymes
and insulin and glucagon degradation, *355

glucose metabolism
and starvation, diabetes, ketone bodies, and free fatty acids, 881-887

heart
cyclic AMP and tolbutamide, *366
insulin receptors in, *354

metabolism
and insulin sensitivity, *720
and intermittent claudication, *798

skeletal
and glucose fatty acid cycle, *347
and glucose uptake by insulin, *385
and glycogen synthase, and glucose and insulin administration, *799

MYOCARDIAL INFARCTION
acute
and plasma free fatty acid levels, *923

and diabetes and prediabetes
and vectorcardiograms, 572-578

and diabetic ketoacidosis, *563

and femoral-popliteal bypass surgery and serum enzyme studies, *372

MYOINOSITOL
metabolism
and diabetes, *348

MYOTONIC DYSTROPHY
and glucose or insulin administration, *799

MYXEDEMA
primary adult
and insulin resistance, *480

N

NAUSEA
and jejunoleal bypass
and liver failure, *921

and nicotinic acid
and hyperlipidemia, 916

NECROBIOSIS LIPOIDICA DIABETICORUM
and skin grafts, *383

NEPHROPATHY
and diabetes onset, *251
and long-standing juvenile diabetes, *357
in Pima Indians, 61-68

NERVOUS SYSTEM
autonomic
and cholinergic modification of glucose-induced insulin release, *800
and diabetes pathogenesis, *860
and hypoglycemia, *342
and impotency in diabetic males, 971-975
and insulin secretion, 494
neuropathy and glucagon response to hypoglycemia, *342

and diabetic neuropathic cachexia, 418-423

motor nerve conduction velocity
and streptozotocin diabetes, *357

parasympathetic
and reactive hypoglycemia, *341

sympathetic
and glucagon response to hypoglycemia, *34

and insulin secretion, *365

NEUROPATHY, DIABETIC
in alloxan diabetic rats, *156

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

and cachexia. *See* Diabetic neuropathic cachexia
 clinical course of, *357
 and glucagon response to hypoglycemia, *342
 and hearing loss, *358
 and impotence, 471-475
 visceral, *860

NIACIN
 metabolism
 in streptozotocin diabetic rats, 977-980

NICOTINAMIDE
 -induced islet cell tumors in rats, *636

NICOTINIC ACID
 and free fatty acid levels
 and glucagon secretion, *797
 and glucose
 and insulin release, *800
 and hyperlipidemia, 916
 and plasma free fatty acid levels
 and glucagon secretion, *860
 and plasma glucose turnover and oxidation, *333-334

NOREPINEPHRINE (NORADRENALINE)
 assays
 in untreated diabetics, 1-8
 and insulin release, *365, *367
 release
 from isolated perfused canine pancreas during glucose deprivation, *481

NUTRITION
 and insulin response
 and ketosis, *377
 and pancreatic alpha cell function, *373

O

OBESITY
 and adipose tissue lipoprotein lipase, *367
 and amino acid metabolism and splanchnic glucose production, *719-720
 and carbohydrate effects on insulin, glucagon and triglyceride levels, *371

in children
 and dietary effects on adipose cell size and glucose tolerance, *719, *797
 and diabetes
 and body weight homeostasis, 318-325
 and plasma alpha-cell glucagon, *923
 and gastric inhibitory polypeptide secretion, *369
 and stress, *379
 and diabetes development, *374
 and false-positive glucagon stimulation tests, *798
 and fasting
 and diurnal changes of plasma glucose, insulin, and glucagon, *371
 and insulin sensitivity, *349
 and glucagon regulation of free fatty acids, *382
 and glucagon tolerance, *383
 and hyperglycemia
 and insulin binding, *354
 and hyperglycemia in mice
 and adrenalectomy, *155-156
 and ventromedial hypothalamic lesions, *334
 and hyperinsulinemia, *920
 and hypertriglyceridemia, *373
 hypothalamic
 and partial hepatectomy, *363
 and insulin
 and glucagon, 657-661
 and insulin binding to rat adipocytes, *380
 and intestinal bypass surgery, *920
 and liver failure, *921
 and metabolism
 and exercise, *368
 and physical training
 and body composition and glucose tolerance, *634
 in rats
 and pancreatic islet structural changes, *253
 and small bowel bypass
 and insulin response to amino acids, *364
 and splanchnic amino acid and glucose metabolism, *797
 and "staircase" glucose stimulation of insulin secretion, 763-769
 and starvation
 and disappearance of Staub-Traugott effect and improved glucose tolerance, *349

and surgery
 and free fatty acid levels, *636
 and weight reduction
 and lipid and carbohydrate metabolism, *799

OCTANOYL CARNITINE
 and diabetic ketoacidosis, 485-493

ORAL CONTRACEPTIVES
 ethynodiol diacetate
 effects on glucose, insulin, and growth hormone, *253-254

ORAL HYPOGLYCEMIC AGENTS
 di-isopropylammonium dichloroacetate, 179-182
 and free fatty acid response to heparin, *994
 and glucagon and insulin secretion in ducks and dogs, 412-415
 and intestinal sugar absorption, 112-115

OUABAIN
 cardiotoxicity
 insulin potentiation of, *353
 and glucose oxidation, 471, 472

OXYGEN
 consumption
 cerebral, *334
 and exercise and obesity, *368
 and glucagon and epinephrine infusion in dogs, *863
 transport
 and sodium bicarbonate therapy in juvenile diabetic ketoacidosis, *924
 uptake
 by *Acetabularia*, insulin and, *368

P

PANCREAS
 adenocarcinoma
 in four siblings, *562
 alpha and beta cell interrelationships in diabetics and normals, *862-863
 alpha-cell function
 and adrenergic system, *154, *860
 and diabetes and obesity, *923
 and oral nutrients, *373
 alpha-cell hypersensitivity to arginine, *344
 artificial endocrine, 389-396

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388
February, 81-160	May, 389-484
March, 161-256	June, 485-564
April, 257-336	July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

clinical trials of, 397-404

autografts

- and endocrine function studies, *359

beta-cell adenoma

- monolayer culture of, *481

beta-cell failure

- and diabetes, *348

beta-cell function

- and acromegaly with diabetic ketoacidosis, *363

beta-cell replication

- and glucocorticoids, *720, *798-799

beta cell response

- and fat absorption, *346
- and glucagon and blood glucose, *635

beta-cell stimulation

- and cyclic AMP-like agents, *385
- and pancreatitis diagnosis, *635

beta cells

- alloxan-toxic receptor studies, *339
- culture on artificial capillaries, *358
- diploid, tetraploid and octaploid, 583-587
- functional segregation of beta granules in, *339
- and glucagon in obesity, *383
- glucose-induced insulin response, 605-609
- response to insulin, *155
- and "staircase" glucose stimulation of insulin in obese patients, 763-769

biopsy, *991

cyclic 3'5'-AMP and insulin release

- and glucose, calcium and ionophore, *337

cystadenoma, *858

of encephalomyocarditis virus-infected mice, *921-922

endocrine

- beta-granule ultrastructure study, *482
- catecholamine inactivation by, 754-761

exocrine

- adenocarcinoma management, *798, *991
- exocrine enzymes

 - and islet cell junctions, *380

- extract

 - cell-mediated immunity to, 693-697

- fetal development

 - and insulin secretion, *340
 - and intermittent glucose infusions in pregnant rats, *634

- fetal rat

development of glucose responsiveness in, *375

and tolbutamide, *862

transplantation into diabetic rats, *989

fetal transplants

- and insulin response to glucose, *366

function

- and somatostatin, *356
- and vagotomy and pyloroplasty, *992-993

gastrin studies, *339

glucagon responses to arginine and somatostatin, *356, 876-879

glucagon secretion

- and adrenergic stimulation, *797, *860
- and plasma free fatty acid levels, *797, *860

infection by Venezuelan equine encephalomyelitis

- in hamsters, *798

insulin content

- of neonatal rats, and maternal tolbutamide injections, *800

insulin and glucagon secretion

- and somatostatin, *356

insulin output

- and central nervous system insulin-sensitive receptors, *341

insulin and proinsulin storage, *860, *994

islet adenoma

- and insulin and proinsulin storage, *860

islet-cell carcinoma

- and streptozotocin, *636

islet-cell changes

- and homogenized islet injections in rats, 579-582

islet-cell function

- and thalassemia, *992

islet cell junctions

- and exocrine pancreatic enzymes, *380

islet cell tumors

- and insulin release, *363

islet cells

- insulin and glucagon localization in, *339

islet permeability

- and alloxan, *377

islet secretion granule membranes

- NADPH binding to, *338

islet tissue

- catecholamine biosynthesis, *363

islet tissue glucose and ATP levels

and diabetes, *340

islet transplantation

- and glomerular lesions in diabetic rats, *359, 748-752
- in rats, *358, *359, *858
- selection of sites for, *359

islet ultrastructural alterations

- and diabetes, *338

islets

- in genetically obese rats, *253
- and glucagon synthesis, *379
- monoamine oxidase, insulin secretion and *338
- and tolbutamide, *560

islets or beta cells

- transplantation, 988

isolated islets from hyperglycemic and normoglycemic rats

- and glucose oxidation and insulin secretion study, 469-473

isolated perfused diabetic mouse

- and hyperglucagonemia, *155

isolated perfused dog

- and acetylcholine-stimulated insulin secretion and calcium, 494-497

and glucose deprivation and noradrenaline release, *481

isolated perfused rat

- and tolbutamide, glibenclamide and glisoxepide comparisons, *924

isolated rat islets

- and alloxan and insulin secretion study, 517-524
- and cytochalasin B inhibition of glucose-induced insulin release, *562
- and glucose regulation of insulin biosynthesis in, *636
- and sorbitol metabolism, *378

microtubules

- and insulin release, *481-482

mouse

- and amylase secretion studies, *858-859

perfused diabetic Chinese hamster

- and insulin and glucagon secretion, *922

perfused rat

- and somatostatin inhibition of insulin and glucagon secretion, *374

perfused rat islets

- and epinephrine and norepinephrine and insulin secretion, *367

perfusion techniques

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

SUBJECT INDEX 1974

and insulin secretion studies, 550-558
 pseudocysts
 and gastrointestinal hemorrhage, *994
 transplantation
 in mice, 183-187
 tumors
 insulin biosynthesis in, *345

PANCREATECTOMY
 and adrenalectomy
 in insulin deficient rats, 144-145
 and enteral glucose administration
 and plasma insulin, total glucagon, and pancreatic glucagon, *344
 and exercise-induced hypoglycemia in dogs, *353
 and glucagon immunoreactivity in dogs, 905-912
 and glucagon secretion and arginine, 512-516
 near total
 and hemorrhagic pancreatitis, *924
 partial
 and glucose tolerance and insulin response in dogs, 429-431

PANCREATITIS
 acute necrotizing
 and surgery, *925
 chronic
 and glucagon responses to arginine, 257-263
 and plasma gastrin responses to arginine, 264-267
 and surgery, *994
 diagnosis
 and oral glucose tolerance tests and beta-cell stimulation, *635
 and glucagon or lactated Ringer solution treatment, *989-990
 hemorrhagic
 and near total pancreatectomy, *924
 treatment, *922

PENTAGASTRIN
 and lower esophageal sphincter pressure, *860

PENTOSE CYCLE, 472

C-PEPTIDE
 assays
 in infants of diabetic mothers, *156
 immunoreactivity
 and infants of diabetic mothers, *921

levels in portal and peripheral blood, *350
 radioimmunoactivity studies
 and insulin secretion in acromegaly with diabetic ketoacidosis, *363

PEPTIDES
 anti-insulin
 and lipolysis and glucose metabolism, *863-864
 from human urine
 insulin potentiation by, 950-956
 synthetic
 and insulin potentiation, 943-949

PHAGOCYTOSIS
 and diabetes, 9-15, 218-220

PHENETHYLBIGUANIDE. *See* Phenformin

PHENFORMIN
 action, *860
 and intestinal absorption studies, *798
 and plasma phenformin levels, *375
 and adipose tissue metabolism, *561
 and carbohydrate absorption, 716-718
 compared with DIPA, 182
 and fibrinolysis in diabetes, *481
 and hyperglycemic rats, 25-27
 and lactic acidosis
 and insulin deficiency, *370
 and mitochondrial calcium fluxes, *369
 and plasma glucose and insulin studies, 624-629

PHENTOLAMINE
 and glucagon secretion, *797
 and insulin release, *365
 and streptozotocin resistance in mice, 857

PHOSPHOENOLPYRUVATE CARBOXYKINASE
 in small-for-gestational-age infants, *991

PHOSPHOFRUCTOKINASE
 in isolated rat hepatocytes and cyclic purine nucleotides, *384

PHOSPHORYLASE
 in neonatal rat liver, *252-253
 mitochondrial
 and insulin, *799-800

PHYTOHEMAGGLUTININ
 lymphocyte transformation response to
 in insulin-dependent diabetics, 708-712

PICS
 and induced hypocalcemia and insulin secretion, *254

PIMA INDIANS
 diabetic nephropathy study in, 61-68
 and glucose tolerance tests, *350

PITUITARY GLAND
 ablation, 698-706
 anti-insulin peptide
 and lipolysis and glucose metabolism, *863-864
 growth hormone biosynthesis and insulin, *334

PLACENTA
 and fetal insulin and glucagon secretion in rats, 311
 histopathological changes in and streptozotocin-induced diabetes in rats, *562
 insulin receptors in, 209-217, *990-991
 membranes
 and radioreceptor insulin assay, *381
 and transfer of streptozotocin in rhesus monkeys, 777-782

PLASMA
 adrenaline
 in children with ketotic hypoglycemia, *921
 alpha-cell glucagon and diabetes and obesity, *923
 catecholamines
 in untreated diabetics, 1-8
 epinephrine and norepinephrine and hypertension, *376
 fibrinogen
 and phenformin and ethylestrenol, *481
 free fatty acid levels
 and acute myocardial infarction, *923
 and glucagon, insulin and growth hormone secretion, *343
 and glucagon secretion, *860
 and glucose loading in dogs, *863
 and obesity, 660-661

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388	August, 645-724
February, 81-160	May, 389-484	September, 725-804
March, 161-256	June, 485-564	October, 805-868
April, 257-336	July, 565-644	November, 869-932
		December, 933-996

SUBJECT INDEX 1974

and pancreatic glucagon secretion, *797
 free fatty acids and insulin
 and exercise, 82-83
 gastrin responses to arginine
 and chronic pancreatitis, 264-267
 glucagon
 and cirrhosis, *635
 and renal failure, *343
 response to fasting and oral glucose
 in diabetic and nondiabetic
 pregnancies, 771-776
 glucagon immunoreactivity
 and depancreatized dogs, 905-912
 in globulin fraction, *343
 and pancreatectomy, 512-516
 glucose
 and tolbutamide and methysergide
 maleate, 21-23
 turnover and oxidation, nicotinic
 acid and, *333-334
 glucose and insulin
 and diphenylhydantoin and hypo-
 glycemia, 680-682
 and phenformin, 624-629
 glucose, insulin, free fatty acids, and
 growth hormone
 and oral alanine in normals and
 diabetics, *720, *797
 glucose, insulin and glucagon
 diurnal changes of, in massively
 obese fasting subjects, *371
 glucose and insulin responses
 and diet in normals, *925
 glucose levels
 and fat free, high carbohydrate diet,
 138-142
 growth hormone
 and exercise in diabetics without
 retinopathy, *924-925
 hyperosmolarity, *860-861
 and ketotic hyperosmolar coma,
 *561
 immunoreactive insulin
 and hypoglycemia, 46-49
 immunoreactive insulin and glucagon
 levels
 and potassium and calcium injections, 55-60
 insulin
 and alcoholic ketoacidosis, 437
 and glucose loading in normal sub-
 jects, 132-136
 and insulin releasing polypeptides,
 902-904
 and pancreatectomy and enteral
 glucose administration, *344
 and "staircase" glucose stimulation,
 767-768
 transient elevation of, blood glucose
 and, *254
 insulin and glucagon
 and protein malnutrition, *719,
 *796
 insulin, glucagon and triglycerides
 and dietary carbohydrate in obese
 subjects, *371
 insulin and glucose
 and insulin resistance, 674-677
 insulin-like activity measurement
 and radioreceptor insulin assay,
 *381
 insulin and lipids
 and intermittent claudication, *720,
 *798
 insulin removal rate
 and glucose infusion, *799
 insulin responses
 and blood glucose concentration,
 *562
 and hyperglycemia control, *352
 lactate and insulin
 and methylprednisolone, *719,
 *796
 lipids
 and glucagon, and hyperlipopro-
 teinemia type, *719, *796
 membrane
 in dogs, *365
 membrane receptors
 for nonsuppressible insulin-like ac-
 tivity in fibroblasts and chon-
 drocyte, *355
 membrane sulfhydryls
 and insulin action on fat cell hexose
 transport, *355
 membranes of human placenta
 insulin receptors in, *990-991
 monosaccharides and polyols
 and hyperglycemia of diabetes, *920
 norepinephrine and epinephrine
 and fasting and insulin, 1-8
 osmolality
 and cerebral edema in nonketotic
 hyperosmolar coma, 525-530
 pancreatic glucagon
 and exercise in rats, 81-92
 phenformin assay
 and phenformin action, *375
 platelet aggregation
 and diabetic retinopathy, *859
 proinsulin
 enzyme and gel filtration assays,
 505-511
 renin activity
 and alloxan diabetes, 962-969
 and diabetes, *368
 and glucagon, *371
 renin response to orthostasis
 in diabetics with orthostatic hypo-
 tension, 835-840
 triglyceride uptake
 and obesity, *367

PNEUMOCOCCAL INFECTION
 and hepatic gluconeogenesis in rat,
 *369

POLYCHONDRITIS
 relapsing
 with insulin resistance and anti-
 bodies to cartilage, *482

POLYETHYLENE GLYCOL
 and glucagon immunoassays, *561

**POLYMORPHONUCLEAR LEUKO-
 CYTES**
 function
 and diabetes control, 9-15

POLYNESIANS
 and diabetes prevalence, 847-848

POLYPEPTIDES
 and growth hormone diabetogenic ef-
 fects, *154
 insulin releasing
 intravenous infusion in rats, 902-904

POLYPLOIDY
 and islets of Langerhans of human
 pancreas, 383-387

POMPE'S DISEASE, *923

POTASSIUM
 depletion
 and fatal diabetic ketoacidosis, *381
 and insulin secretion, 933-941
 intrapancreatic injections of
 and glucagon secretion in dogs,
 55-60
 therapy
 and diabetic ketoacidosis, electro-
 cardiographic monitoring of,
 610-615
 uptake
 and growth hormone dosages, 501,
 503

PRADER-WILLI SYNDROME
 and immunoreactive insulin and

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

SUBJECT INDEX 1974

growth hormone responses, *156

PREDIABETES
and glucose-induced insulin response
and arginine, 161-170
and glucose tolerance, *154
and insulin responses, *351
and vectorcardiographic studies, 572-58

PREGNANCY
and alloxan diabetes
and carbohydrate metabolism in fetal rat heart, 662-667
and carbohydrate metabolism, 771-776
in cows
and insulin secretion, *334
and fasting hypoglycemia
and glucose kinetics and insulin, *342
and insulin, growth hormone and prolactin binding studies, *991
in rats
and fetal insulin and glucagon secretion studies, 310-316
and intermittent glucose infusion effect on fetal pancreatic beta cell development, *634
and tolbutamide effects on pancreatic insulin content of neonatal rats, *800
and tolbutamide injections, *862
in rhesus monkeys
and placental transfer of streptozotocin, 777-782

PREGNANCY, DIABETIC
and carbohydrate metabolism, 771-776
and chlorpropamide
and fetal outcome, *862
and fetal perinatal mortality, 302-305
and insulin
and C-peptide immunoreactivity in neonates, *921
and insulin antibodies, *859

PREMATURITY
and glucose metabolism and insulin secretion, 172-177

PROGESTOGENS
ethynodiol diacetate
and glucose, insulin and growth

hormone effects, *253-255

PROINSULIN
assays
insulin specific protease and gel filtration, 505-511
biosynthesis, *340
and chemical diabetes of childhood and adolescence, *382
conversion to insulin and C-peptide in pregnant diabetics and neonates, *921
glucagon-induced rise in and insulinomas, *377
in insulin antibody precipitin study, *480
intake
and liver gluconeogenesis, 869-874
levels in portal and peripheral blood, *350
metabolism, *994
storage
in islet adenoma and pancreas, *860
synthesis, *338

PROLACTIN
-binding studies, *991

PROPANTHELINE
and cholinergic blockade, *341

PROPRANOLOL
and epinephrine test
and ketosis-resistant diabetes, 269-274
and glucagon secretion, *860

PROSTAGLANDINS
and glucose turnover in rats, 532-535

PROTEIN(S)
deficiency
and plasma insulin and glucagon, *719, *796
glucagon-binding
from liver plasma membranes, *990
insulin-binding
and hypoglycemia, 41-49
leucine incorporation into and trypsin, *252
metabolism
and diabetic microangiopathy, *378
in rat hepatocytes, *384
phosphorylation
in adipocytes, and insulin and epinephrine, *348
synthesis

glomerular, in streptozotocin diabetic rats, *357

PROTEINURIA
and diabetic nephropathy in Pima Indians, 62-68

PSEUDOCYSTS
pancreatic, *994

PUROMYCIN
and glucose oxidation, 471, 472

PYLOROPLASTY
and pancreas and gall bladder function, *993

PYRUVATE
metabolism
and insulin, *154

R

RABBITS
and cerebral glucose transport and oxygen consumption, *334
and 2-deoxy-D-glucose infusion into hepatic-portal system
and food intake, *636
and insulin potentiation by human urine peptide fraction, 952, 953
and mitochondrial metabolism
and insulin, *799-800

RACE
and diabetes prevalence among American Indian tribes and other native populations, 841-852
and serum and urine glucose response to oral glucose challenge, 327-332

RATS
adipocytes
insulin binding to, *380
alloxan diabetic
and hypercholesterolemia, *799
and neuropathy, *156
and overt diabetes in offspring, *346
and renin, angiotensin and nor-epinephrine, 962-969
beta-cell tumors
and insulin biosynthesis, *345
and carbohydrate loading

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388	August, 645-724
February, 81-160	May, 389-484	September, 725-804
March, 161-256	June, 485-564	October, 805-868
April, 257-336	July, 565-644	November, 869-932
		December, 933-996

SUBJECT INDEX 1974

and liver glucose 6-phosphate dehydrogenase and malic enzyme, *990

diabetic

- and acid-base status and tissue glycogen, *991
- and pancreatic islet transplantation, 748-752

dichloroacetate treated

- and liver enzyme activities, *364

epididymal adipose tissue

- and insulin administration, *482

and exercise-induced glucagon secretion, 81-92

fasted and fed

- and exercise and blood glucose and lactate, *368

and fatty acid-enriched diet

- and beta cell insulin response to glucose, 605-609

genetically obese

- and pancreatic islet structural changes, *253

and glucagon-induced hypocalcemia, and hypophosphatemia, *989

and glucose metabolism

- and prostaglandins, 532-535

glucose-U-14-C and fructose-U-14-C incorporation into liver, plasma, and adipose tissue triglyceride, *155

and growth hormone biosynthesis and insulin, *334

heart

- and tolbutamide, *366

hepatocytes

- and phosphofructokinase, *384

and high-fat diet

- and hepatic gluconeogenesis and glucagon secretion, 869-874

and homogenized islet injections and islet cell changes, 579-582

and hyperglycemia

- and beta cell function, *340
- and phenformin, 25-27

hyperglycemic and normoglycemic and pancreatic islets glucose oxidation and insulin secretion studies, 469-473

and hypoglycemia

- and brain development, *635
- with hypothalamic obesity and partial hepatectomy, *363

insulin deficient

- and adrenalectomy, 143-149

and hypertriglyceridemia, *346

and insulin potentiation by human urine peptide fraction, 952, 953

and insulin release

- and chlorpromazine, *634
- and intravenous infusion of insulin releasing polypeptides and insulin release, 902-904

and ketotic diabetes

- and pancreatic islet transplantation, *358

liver glutathione-insulin transhydrogenase

- insulin control of, 117-124

neonatal

- and alanine and ketone body metabolism, *380

and obesity

- and diabetes development, *374

pancreas perfused in situ

- and somatostatin inhibition of glucagon and insulin secretion, *374

perfused liver

- insulin binding and degradation in, *354

perfused pancreas islets

- and insulin secretion and epinephrine and norepinephrine, *367

pregnant

- and fasting hypoglycemia and glucose kinetics, *342
- and glucose infusions and fetal pancreatic beta cell development, *634
- and tolbutamide effect on offspring, *862

protein deficient

- and plasma insulin and glucagon levels, *719, *796

skeletal muscle

- glucose metabolism studies, *347, 881-887

streptozotocin diabetic

- and apoprotein composition and lipoprotein lipase activity, *364
- and di-isopropylammonium dichloroacetate treatment, 179-182
- and diazoxide, 282-285
- and diet and DNA synthesis study, 793-794
- and glomerular protein synthesis, *357
- and glycogen accumulation in retinal neurons and glial cells, 221-231

and leucine metabolism in muscles and nerves, *366

and motor nerve conduction velocity, *357

and pancreatic islet-cell transplantation, *858

and placental changes, *562

and portal vein islet isografts and allografts, *359

and tryptophan-niacin metabolism, 977-980

and streptozotocin and nicotinamide induced islet cell tumors, *636

and sucrose-induced diabetes

- and testicular degeneration, *720, *800

and sugar transport

- and oral hypoglycemic agents, 112-115

with ventromedial hypothalamic lesions

- and insulin and growth hormone secretion, 203-208

and virus-induced latent diabetes, *381

RENIN

- release and glucagon, *371

RETICULOENDOTHELIAL SYSTEM

- phagocytosis and diabetes, 218-220

RETINA

- and basal lamina layering in diabetes, 98, 100
- glycogen accumulation in streptozotocin diabetic rats, 221-231

RETINOPATHY, DIABETIC

- and diabetic control, *482
- and exercise and plasma growth hormone levels, *924-925
- and hypophysectomy, 698-706
- and phagocytosis of reticuloendothelial system, 218, 219
- and platelet aggregation, *859
- and sucrose-induced diabetes in rats, *800
- and vasopressor responsiveness, *368

RHESUS MONKEYS. See also

- Monkeys
- and glucose metabolism and pneumococcal sepsis, 544-548

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

- January, 1-80
- February, 81-160
- March, 161-256
- April, 257-336

- Supplement 1, 337-388
- May, 389-484
- June, 485-564
- July, 565-644

- August, 645-724
- September, 725-804
- October, 805-868
- November, 869-932
- December, 933-996

SUBJECT INDEX 1974

RIBOSOMES
from rat diaphragm muscle
and insulin and denervation, *993

RNA
and insulin biosynthesis, *636
metabolism
in cultured human fibroblasts, 445,
447-448
and proinsulin synthesis, *338

S

SALMONELLA TYPHIMURIUM
infection
and growth hormone responses,
*375

SCIATIC NERVE
myelin
I-¹⁴C-leucine incorporation into, in-
sulin and, *358

SECRETIN
immunoreactive
and intraduodenal administration of
hydrochloric acid and glu-
cose, *796
and insulin response to hydrochloric
acid, *719
and intestinal disaccharidase release,
*990

SENSORIUM
depression of
and nonketotic hyperosmolar coma,
525-530

SERUM
anti-insulin
reactivity to insulin, *376
cholesterol
and cardiovascular disease and
diabetes, 107
and high- and low-carbohydrate
diets, *994
and liver metabolism, *989
pathogenesis, *796
creatinine
and diabetes duration, 65
enzymes
and diabetic ketoacidosis, 126-131
and femoral-popliteal bypass
surgery, *372
free fatty acids
and ketosis-resistant diabetes,
271-272, 274
gastrin
and familial multiple endocrine

adenomatosis, *925
and glucagon, *480
glucose and insulin
and intravenous ethanol, 822
glucose, insulin, free fatty acids,
glycerol, triglycerides and
glucagon
and exercise and obesity, *368
glucose levels
and anthropometric measurements,
*365
glucose response to glucose challenge
and race, 327-332

growth hormone
in genetically potential diabetics,
*253

haptoglobin levels
and insulin-induced hypoglycemia,
151-153

insulin
in genetically potential diabetics,
*253

insulin and free fatty acids
and epinephrine, 743-746

insulin and growth hormone responses
in twins with juvenile diabetic
twin-mate, *350

insulin levels
and exogenous insulin administra-
tion, *154-155

lipids and lipoproteins
and hemodialysis, *71, *251

polymorphonuclear leukocytes
and diabetic control, 11-15

proinsulin
and chemical diabetes, *382

proteins
and diabetic microangiopathy, *378

sorbitol
and diabetes, *920

triglyceride levels
and estrogen and hyperinsulinemia,
*373

SEX
and alcoholic ketoacidosis prevalence,
438-439
and cardiovascular disease and dia-
betes, 110-111
and diabetes prevalence, 106, 107
and diabetic nephropathy, 63
and plasma catecholamine assays, 2, 3
and post-glucose loading glycosuria,
189
and reticuloendothelial system
phagocytosis, 219

SEXUAL FUNCTION
in diabetic men, 306-309, 971-975

SHEEP
and cerebral glucose transport and ox-
ygen consumption, *334

SHOCK
hypovolemic
and insulin release, *635
and ketoacidosis therapy, *859

SKIN
erythema
and glibenclamide hypersensitivity,
739-742

fibroblasts
insulin action on, 443-448

and glucagonoma syndrome, *861

grafts
and necrobiosis lipoidica dia-
beticorum in juvenile dia-
betes, *383

rashes
and sulfonylureas, 741

SODIUM
and insulin secretion, 933
retention
and insulin therapy in diabetics,
240-246

SODIUM BICARBONATE
and diabetic ketoacidosis, *859, *992
and juvenile diabetic ketoacidosis
and oxygen transport, *924
metabolic effects of, 405-411

SODIUM LACTATE
and inhibition of lipolysis, *989

SOMANTIN
and insulin antagonistic effects of
growth hormone, *154

SOMATOMEDIN
deficiency, *863
and growth hormone
and diabetes, 786

SOMATOSTATIN
and glucagon and insulin secretion,
*374
and insulin-glucagon ratio
in normal and diabetic dogs, *356
and insulin secretion, *989
and pancreatic endocrine function,
*356
and pancreatic glucagon responses to
arginine
and diabetes, 876-879

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388
February, 81-160	May, 389-484
March, 161-256	June, 485-564
April, 257-336	July, 565-644
	August, 645-724
	September, 725-804
	October, 805-868
	November, 869-932
	December, 933-996

SUBJECT INDEX 1974

and pancreatic insulin and glucagon secretion, *356

SORBITOL
metabolism
in isolated pancreatic islets, *378

SORBITOL PATHWAY
and aldose reductase, 460-467
and glucose action, *378

SPERMATOGENESIS
reduced
in sucrose-induced diabetic rats, *800

SPLANCHNIC NERVE
and gluconeogenesis
and exercise, *384
glucose and amino acid metabolism
and obesity, *797
glucose production
and obesity, *719-720

SPLEEN
and glibenclamide hypersensitivity reaction, 740

STARVATION. See also Fasting
and alanine-stimulated insulin and glucagon secretion, *481
and carbohydrate loading in rats
and liver glucose-6-phosphate dehydrogenase and malic enzyme, *990
and fatty acid-enriched rats
and insulin response to glucose, 605-609
and glucose metabolism in skeletal muscle, *347
-induced ketosis
and odd-carbon fatty acids, *925
and insulin
and ketosis, *377
and ketone body production, *349
and liver glutathione-insulin transhydrogenase in rats, 121
and obesity
and insulin sensitivity, *349
and skeletal muscle glucose metabolism in rats, 881-887
and streptozotocin diabetes
and skeletal muscle metabolism in rats, 883-885

STAUB-TRAUGOTT EFFECT
disappearance of
and intravenous glucose loading, *349

STEROIDS
and renal transplantation
and hyperglycemic nonketotic coma, *992

STREPTOZOTOCIN
action
on mouse islets of Langerhans, *373
-induced diabetes in mice
and pancreas transplantation, 183-187
-induced diabetes in rats
and apoprotein composition and lipoprotein lipase activity, *364
and diazoxide, 282-285
and diet and DNA synthesis study, 793-794
and di-isopropylammonium dichloroacetate treatment, 179-182
and glomerular protein synthesis, *357
and glycogen accumulation in retinal neurons and glial cells, 221-231
and insulin binding and degradation in perfused liver, *354
and leucine metabolism in muscles and nerves, *366
and motor nerve conduction velocity, *357
and muscle metabolism studies, 881-887
and obesity, *374
and pancreas islet-cell transplantation, *858
and pancreatic islet transplantation, *358, *359, 748-752
and pancreatic portal vein islet isografts and allografts, *359
in perinatal period, 889-894
and placental changes, *562
and renal gluconeogenesis control, *373
and renin angiotensin system, 967
and tryptophan-niacin metabolism, 977-980
-induced islet-cell tumors in rats, *636
placental transfer of
in rhesus monkeys, 777-782
resistance
in KK mouse, 856-857
therapy
for islet cell carcinoma, *636

STRESS
and epinephrine, 743-746

and hyperglycemic nonketotic coma
after renal transplantation, *992
and obesity
and diabetes, *379

SUCROSE
-induced diabetes in rats
and testicular degeneration, *720, *800

SUGAR
alcohol accumulation
and aldose reductase, 460-461
consumption
and diabetes among American Indians, 850-851
intestinal absorption of
and oral hypoglycemics, 112-115

SULFHYDRYL
and insulin and glucagon degrading by enzymes, 539-540

SULFONAMIDES
and glucagon and insulin secretion in ducks and dogs, 412-415
and hypoglycemic coma, *634-635

SULFONYLUREAS
action mechanisms, *155
derivatives
glipizide and glibenclamide, *333
glibenclamide
hypersensitivity reaction to, 739-742
glibenclamide and glisoxepide, *923-924

SURGERY. See also Transplantation
and acute necrotizing pancreatitis, *925
and adenocarcinoma of exocrine pancreas, *798, *991
adrenalectomy. *See Adrenalectomy*
and chronic pancreatitis, *994
and cystadenoma of pancreas, *858
and fatty acid toxicity, *635-636
femoral-popliteal bypass
and serum enzymes, *372
gastrojejunostomy
and glucose tolerance tests, *993
and hyperosmolar coma, *634
hypophsectomy
and diabetic retinopathy, 698-706
and insulinomas, *994

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

intestinal bypass
and obesity, *920
jejunointestinal bypass
and liver failure, *921
lower limb amputation
and mortality rates, 287-292
pancreatectomy
and enteral glucose administration,
*344
and glucagon immunoreactivity in
dogs, 905-912
and glucagon secretion, 512-516
and hemorrhagic pancreatitis, *924
partial pancreatectomy
and glucose tolerance and insulin
responses in dogs, 429-431
small bowel bypass
and insulin response to oral amino
acids, *364
vagotomy and pyloroplasty
and pancreas and gall bladder func-
tion, *992-993

T

TES-TAPE
evaluation of, 474-479

TESTICLES
degeneration
in sucrose-induced diabetic rats,
*800

TETRACAIN
and acetylcholine-induced insulin se-
cretion, 495

THALASSEMIA
and pancreatic islet cell function
and glucose tolerance, *992

THEOPHYLLINE
alpha cell hypersensitivity to, *344

THYMIDINE
incorporation into DNA
and nonsuppressible insulin-like ac-
tivity, *355

³H-THYMIDINE
incorporation into islet DNA
and streptozotocin, *373

THYMIDINE METHYL-³H
incorporation into DNA
in intestine of diabetic rats, 793-794

THYROID
function
and free fatty acids, *562
and insulin secretion, *154

THYROTOXICOSIS
oral glucose tolerance tests during,
*154

D-THYROXINE
and hyperlipidemia, 916

TISSUE
adipose. *See Adipose tissue*
aldose reductase
purification and immunologic iden-
tification technique, 460-467
epididymal adipose
of lean and obese-hyperglycemic
mice, *251
glycogen
and acid-base status in normal and
diabetic rats, *991
and insulin potentiation
and peptide fraction from human
urine, 950-956
isolated human adipocytes
insulin binding to, 565-570
ligated pancreatic transplants
in diabetic mice, 183-187
metabolites
and glucose and insulin administra-
tion in starved rats, 885
muscle and nerve from diabetic rats
and leucine metabolism study, *366
pancreatic
lymphocytic infiltration of, *386
and proteolytic enzymes effect on
islet cell junctions, *380
transplantation of, 988
pancreatic fragments
perfusion techniques, 550-558
pancreatic islet
and glucose and ATP levels, *340
placental
insulin receptors studies in, 209-217
rat diaphragm muscle
and ribosome activity, *993
rat epididymal adipose
and pyruvate metabolism and insu-
lin, *154
rat hemidiaphragm
glucose uptake, and synthetic pep-
tides, 944, 945
rat islet
and insulin biosynthesis studies,
*345

TOLBUTAMIDE
comparisons with glibenclamide and
glisoxepide, *923-924
and false-positive glucagon stimulation
tests, *798
and glucagon and insulin secretion
in ducks and dogs, 412-415
and glucose-mediated insulin re-
sponse
and ethanol preinfusion, 821-825
and heart contractility and cyclic AMP
concentration, *366
and immunoreactive insulin secretion
by perfused rat pancreas, 555
-induced insulin release
and alloxan, 521-522
and methysergide maleate, 21-23
injections in pregnant rats and pan-
creatic insulin content of
offspring, *800, *862
insulin response to
in "essential" and "pancreatic" mild
glucose intolerance, 896-901
and hypovolemic shock, *635
from normal pancreatic islets, *560
and intestinal sugar absorption,
112-115
intravenous
and glucose, insulin and tol-
butamide dynamics in normal
subjects, *372
in isolated rat fat cells
and lipolysis, 51-54
tests
and chronic renal failure, *375
and methysergide maleate, 21-23
and serum insulin and intravenous
ethanol, 823
and termination of insulin therapy,
*378

TOXEMIA
and fetal mortality in diabetic preg-
nancy, 302

TRANSPLANTATION
of fetal pancreas into diabetic rats,
*989
and insulin response to glucose,
*366
kidney
hyperglycemic nonketotic coma
after, *992
and juvenile diabetes, *357
of pancreas
as cure for diabetes, 987-988
in diabetic mice, 183-187
and endocrine function, *359

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

SUBJECT INDEX 1974

pancreas islet-cell, *858
 and glomerular lesions in diabetic rats, 748-752
 in severe, ketotic diabetic rats, *358
 and site selection, *359

TRAUMA
 and sympathectomy
 and glucagon response to hypoglycemia, *342

TRIGLYCERIDE
 levels
 and diabetes control, *379
 metabolism
 and clofibrate, *859

TROPICS
 ketosis-resistant diabetes in, 268-274

TRYPSIN
 and isolated fat cells
 and inhibition of insulin effects on leucine incorporation into protein, *252

TRYPTOPHAN
 metabolism
 in streptozotocin diabetic rats, 977-980

TUMORS
 alpha cell
 and glucagonoma syndrome, *861
 beta-cell adenoma
 monolayer culture of, *481
 carcinoid, of duodenum, pancreas and stomach
 and glucagon and gastrin, *922
 cystadenoma of pancreas, *858
 of duodenal wall
 and Zollinger-Ellison syndrome, *864
 gastrinoma
 and gastrojejunostomy, and glucose tolerance tests, *993
 insulinomas
 diagnosis and surgery, *994
 and glucagon-induced insulin response, *992
 and glucagon-induced proinsulin rise, *377
 and glucagon stimulation tests, *798
 islet-cell
 and catecholamine biosynthesis, *363
 streptozotocin and nicotinamide-induced, *636

pancreatic
 insulin biosynthesis in, *345
 pancreatic islet adenoma, *363
 and insulin and proinsulin storage, *860

TWINS
 with juvenile diabetic twin-mate
 serum insulin and growth hormone responses in, *350
 and oral glucose-stimulated insulin release studies, 684-691

U

ULCER
 duodenal
 and glucagon and gastrin release, *480

UREMIA
 and diabetes
 and monosaccharides and polyols, *920
 and glucose tolerance tests, *375

URIC ACID
 metabolism
 and carbohydrates, *993

URIDINE
 incorporation into RNA
 and hormones, 447-448

URINE
 catecholamines
 and glucose lowering, *341
 glucose and ketone semiquantitative determinations
 evaluation of, 474-479
 glucose response to oral glucose and race, 327-332
 n-hexanedioic and n-octanedioic acid excretion
 in juvenile diabetics with ketonuria, 16-20
 insulin antagonist
 and lipoatrophic diabetes, *385
 ketone bodies
 and lactate, *379
 and starvation, *349
 niacin and N¹-methylnicotinamide in streptozotocin diabetic rats, 977-980
 octanoylcarnitine, 486-487
 peptide fraction
 insulin potentiation by, 950-956

sodium excretion
 and insulin therapy in diabetes, 240-246

V

VAGOTOMY
 and pancreas and gall bladder function, *993

VASCULAR DISEASE
 arteriosclerotic
 and hyperlipidemia, 913
 and diabetes, *482
 in American Indian tribes, 848-849
 and oral hypoglycemic agents, 181
 and red blood cell 2, 3, diphosphoglycerate, *374
 and growth hormone
 and diabetes, 783-787
 and plasma growth hormone abnormalities, *924-925

VECTORCARDIOGRAMS
 and diabetes
 and myocardial infarction or "bites," 572-578

VEINS
 portal and peripheral
 immunoreactive glucagon, arginine and glucose infusions in, 199-202

VENEZUELAN EQUINE ENCEPHALITIS VIRUS
 -induced diabetes, *345
 and pancreatic infection in hamsters, *860

VERTIGO
 and auditory nerve dysfunction
 and diabetic neuropathy, *358

VINCRISTINE
 and insulin release, *481-482

VIRUSES
 Coxsackie B4
 and diabetes, *345
 and diabetes pathogenesis, 631-632
 encephalomyocarditis
 diabetes induced by, *923
 and islets of Langerhans lesions in mice, *921-922
 and induced diabetes, *381
 and intracellular redox state
 and hepatic gluconeogenesis, *369

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

SUBJECT INDEX 1974

and mild illness
and carbohydrate metabolism, *482
Salmonella typhimurium
and growth hormone responses to
fructose and glucose, *375
Venezuelan equine encephalitis
and diabetes, *345
and pancreatic infection, *798, *860

VOMITING
and liver failure
and jejunoileal bypass, *921

W

WEIGHT. *See* **Body, weight; Obesity**

X

XANTHURENIC ACID
in streptozotocin diabetic rats, 978

Z

ZOLLINGER-ELLISON SYNDROME,
192, *561
and duodenal wall tumor, *864
and glucagon and gastrin release, *480

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
February, 81-160
March, 161-256
April, 257-336

Supplement 1, 337-388
May, 389-484
June, 485-564
July, 565-644

August, 645-724
September, 725-804
October, 805-868
November, 869-932
December, 933-996

AUTHOR INDEX 1974

In this index are the names of authors of articles that have appeared in **DIABETES** and those whose articles have been abstracted in the Journal during 1974. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Subject Index appears on page 1.

A

Abbiati, R., *333
 Abendschein, D., *363
 Abraham, R.R., *251
 Abramovici, A., *562
 Abratra, C., *349
 Adam, Peter A.J., 816-820
 Adams, Donald A., 698-707
 Adcock, K., *363
 Adloph, W., *482
 Ahuja, M.M.S., *156
 Aiello, Lloyd M., *368
 Ajlouni, Kamel, *351
 Ajmani, Narinder K., 268-275
 Akarte, Nilkanth R., 977-981
 Akgun, S., *363
 Alberti, K.G.M.M., *480, *989
 Albisser, A.M., 389-396, 397-404
 Albrink, Margaret J., 913-918
 Aliapoulios, M.A., *989
 Allan, Frank N., 69-71
 Allen, B.T., *363
 Allen, Donald O., 51-54
 Aloia, J.F., *920
 Alric, R., *923-924
 Altszuler, N., *719, *796
 Amamoo, D.G., *858
 Amatruda, J., *364
 Ammon, H.P.T., *634
 Andersen, Bjørn, 302-305
 Andersen, O., 821-826
 Anderson, James W., *364, *379
 Andreani, D., *480
 Andres, R., *341
 Andrews, Samuel S., 199-202, *365
 Anthony, L.E., *719, *796
 Aoki, Thomas T., *364, 405-411, 512-516
 Aparicio, Nestor J., 132-137
 Arcangeli, M.A., *339, *382
 Ardill, J., 264-275
 Arieff, Allen I., *352, 525-531
 Arky, Ronald A., 240-246
 Armstrong J. McD., *154
 Arora, K.K., *251
 Arquilla, E.R., *353
 Artini, D., *333
 Ashmore, James, 51-54

Asplund, K., *634
 Assal, Jean-Ph., 405-411, *994
 Assan, Roger, 310-317, 732-738
 Ater, Joann L., *383
 Atkinson, M.K., *251
 Aubry, F., *719, *796
 Austin, M., *363
 Avruch, Joseph, *348

B

Baber, J.C., *920
 Bagdade, J.D., 9-15, *920
 Bailey, C.P., *385
 Baird, Joyce D., *251
 Balasse, E.O., *333-334, *349
 Baldridge, John A., 21-24
 Ballinger, Walter F., *359
 Bank, S., 257-263, 264-275
 Bansal, D.D., *480
 Barbosa, J., *799
 Barker, C.F., *359
 Barnes, A.J., *858
 Barnett, Donald M., 306-309
 Bar-on, Hanoch, *364
 Bartelheimer, Heinrich, *379
 Batchelder, T., *562, *799
 Bauer, G. Eric, *345, *379
 Baumgartner, C. John, *359
 Beall, F.A., *369
 Beaumont, Paul, 221-231
 Becker, H.D., *480
 Beisel, William R., *375, *482
 Belfiore, Francesco, 293-301
 Bell, Benjamin, *365
 Benditt, E.P., *863
 Benedict, G.W., *340
 Bennett, M.A., *562-563, 610-615
 Bennett, P.H., 61-68, *345, *350, *351
 Berger, Michael, *347, 881-888
 Berken, Arthur, 218-220
 Berman, Bruce G., *154
 Bernardis, L.L., *334, *363
 Berne, C.J., *799
 Berquist, K., *345
 Bertrand, J., *990-991
 Bessman, Alice N., 287-292, *374
 Betteridge, A., *334

Beveridge, G.W., 739-742
 Bewsher, P.D., *862
 Bhuyan, Biyoy K., 777-782
 Bier, Dennis M., 982-986
 Bierman, Edwin L., 138-142, *348,
 *351, 624-630, *920
 Binkiewicz, A., *858
 Birge, Clifford, 827-834
 Birk, S.A., *253-254
 Bjerknes, C., *719, *796
 Björntorp, Per, *634, *720, *798
 Blackard, William G., 199-202, *350,
 *365, 550-559
 Blackburn, G.L., *859
 Blackwell, S.W., *634
 Blanks, M.C., *921
 Blecher, M., *990
 Bloch, D., *333
 Block, Marshall B., *154-155, 589-596,
 *921
 Bloodworth, J.M.B., Jr., *365
 Bloom, A., *858
 Bloom, S.R., *861
 Blum, J.W., *334
 Blum, M. Robert, 192-198
 Boden, Guenther, *253, *349, *482,
 *719, *796
 Bonar, Jeanne Rae, *385
 Bonnet, D., *990
 Bornstein, Joseph, *154, 943-949,
 950-956
 Bortz, Walter M., *796, *989
 Bosch, A.L., *347
 Botros, M., 112-116
 Botz, C.K., 389-396, 397-404
 Boucher, W., *923
 Boulter, Philip R., 240-246
 Bouman, Paul R., 203-208
 Bourdillon, C., *994
 Bourel, M., *636
 Bower, R., *381
 Boxer, J., *921
 Boyd, A.E., III, *796, *989
 Braaten, Jan T., 835-840
 Brancato, P., *636
 Brandenburg, D., *560-561
 Bray, George A., *367, *371, *374
 Brennan, M.F., 512-516

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

AUTHOR INDEX 1974

Brenner, William L., *634
 Bresgen, H.A., *379
 Brodows, R.G., *365, *367
 Brogard, J-M, *634-635
 Brooks, C.G.D., *719, *797
 Broun, G., *994
 Broun, J., *989
 Brown, David M., *359, 748-753
 Brown, Harold, *367
 Brown, Joseph D., *366
 Brown, Josiah, *366
 Brown, M., *480
 Brown, R.A., *922
 Brown, R.G., *921
 Brundin, T., *719-720, *797
 Brunswig, D., *636
 Brunzell, John D., 138-142, *348, *351, 624-630, *920
 Buchanan, K.D., 257-263, 264-275, *339
 Buckman, Maire, *369
 Buchwald, H., *921
 Buckman, M.T., *481
 Buhi, W.C., *253-254
 Bulger, Roger J., 9-15
 Burke, Jack P., *339
 Burney, Stephen W., *365
 Burns, Thomas W., *347
 Burns-Cox, C.J., *634
 Burr, I.M., 282-286, *800, *861-862
 Burrill, Karen C., 276-281, 763-770
 Burrows, Belton A., *381
 Buschbom, Ray L., 957-961
 Buse, Maria G., *366
 Butcher, Dennis L., *366

C

Cahill, G.F., Jr., *339, *364, *368
 Campbell, C.J., 694-697, 708-712
 Campbell, I.W., *739-742
 Campbell, R.C., *365, *367
 Campfield, L.A., *367
 Canivet, J., *924-925
 Cardon, P.V., 743-747
 Carpenter, A-M, *375
 Carroll, Hugh J., 525-531
 Carter, James R., Jr., *347
 Casara, Dario, *154, *560
 Cassady, G., *922
 Castro, J., *720, *797
 Cataland, Samuel, *369
 Cathcart, Edgar S., 460-468
 Cerasi, Erol, *154, 161-171
 Cerchio, G.M., *635
 Cervantes, C., *156
 Chacra, A.R., *348
 Chakrabarti, R., *481
 Chandler, Michael L., 232-239

Chapman, Barbara A., *338, 754-762
 Charles, A., *337
 Chase, Gerald R., 474-479
 Chase, H.P., *635
 Chazan, Joseph A., *251
 Chen, Mei, *341- *356
 Cheng, Jose, *367
 Chernigoy, Franz A., *635-636
 Cherrington, A.D., 805-815
 Cheung, L., *858
 Chez, Ronald A., 777-782
 Chiasson, J-L., *349, *367
 Chick, William L., *358, *481, *720, *798-799
 Chidekel, E., *356
 Ching, K.-N., 763-770
 Chlouverakis, C., *334, *368
 Christacopoulos, P.D., *368, *375
 Christensen, N.J., 1-8, *481, *921, *989
 Christensen, S.E., *989
 Christlieb, A. Richard, *368, *372, 835-840, 962-970
 Chronis, S.D., *375
 Civetta, J.M., *925
 Clark, Charles M., Jr., 662-668
 Clark, M.G., *347
 Clark, W., *989
 Clark, W.R., *366
 Clarke, B.F., 739-742, *992
 Classen, M., *864
 Clements, Rex S., Jr., *348
 Coddling, J.A., 424-432
 Cohen, A.M., *720, *800
 Cohen, Margo P., *357
 Cole, Edward H., *340, 469-473
 Cole, H.S., *858
 Cole, R.A., *340
 Collen, Morris F., 327-332
 Collins, Mary E., 669-673
 Colome, S., *799
 Colwell, J., *859
 Conard, V., *368
 Conaway, Howard H., 494-498
 Condon, R.E., *989-990
 Condorelli, M., 532-535
 Conforti, Alberto, *154
 Congdon, C.C., 183-188
 Coniglione, T.C., *385
 Connolly, J.H., *480
 Conway, Martin J., *369, *481
 Cook, J., *800, *861-862
 Cooke, N.J., *992
 Cooperman, Michael T., 433-439
 Corbett, V.A., *346
 Corkey, B.E., *337
 Cormack, J.D., *862
 Cornblath, Marvin, *380
 Cowan, J.S., *863

Cowden, L.B., *382
 Cox, B., *861
 Crabtree, R.E., *352
 Craighead, J.E., *921-922
 Cresto, Juan C., *377, 505-511
 Crockett, Samuel E., *369
 Crowley, M.F., *858
 Cryer, Philip E., 982-986
 Cuatrecasas, Pedro, *481, *990
 Culbert, S., 282-286, *800, *861-862
 Curnow, Randall T., *345, *369, *482
 Czech, Michael P., *355
 Czerwinski, C., *635

D

Dabiere, C.S., *635
 Daggett, W.M., *925
 Dahllof, A.G., *720, *798
 Dailly, R., *923
 Dales, Loring G., 327-332
 Daniel, Robert R., 771-776
 Danielsson, A., *858-859
 Dashe, Alfred M., 698-707
 Datta, P., 268-275
 Daturi, S., *333
 Davidoff, Frank, *358, *369, 433-439
 Davidovac, Z., 389-396, 397-404
 Davidson, J.A., *352
 Davidson, J.K., *352
 Davidson, M.B., *354
 Davignon, J., *719, *796
 Davis, Eli, *386
 Davis, John W., 589-596
 Deaciuc, Ioan V., *386
 DeBaere, H., *334
 De Bra, D.W., Jr., *352
 Decraene, P., *334
 DeFronzo, R.A., *341
 Degenhart, H.J., *863
 dejesus, P.V., *357
 de Jounge, Kristina, *634
 DeLamater, P.V., *254
 DeLeeuw, I., *334
 Dembo, A.J., *370
 De Meyts, P., *355
 DeMiguel, Raul, 132-137
 Derojas, Juan F., *370
 Derr, R.F., *990
 DeSantis, R., *635
 Devis, G., *481-482
 Diaz-Fierros, Maruxa, *635
 Diego, Javier, *635
 Digironimo, Mario, *370
 Dippe, Stephen E., 61-68, 192-198, *345, *350, *351, 589-596
 Dixit, P.K., *345
 Dixon, K., *859

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

AUTHOR INDEX 1974

Dobbie, J.G., *859
 Dobbs, R., *346
 Doe, Richard P., *342
 Donev, Stojco, *482
 Donovan, J.L., *858
 Dorner, M., *634-635
 Doron, M., *480
 Downs, R.W., Jr., *363
 Dreyer, N., *561
 Driscoll, T., *373
 DuCaju, M.V.L., *863
 Duckworth, William C., *355, *363, *382, 536-543
 Dunbar, J.C., *560
 Duncan, L.J.P., 694-697, 708-712
 Duran, Tomas A., *370
 Dweck, H.S., *922
 Dyck, W.P., *990

E

Eaton, R. Philip, *344, *369, *382, *481, 657-661, *859
 Eder, Howard A., *364
 Efendić, Suad, 161-171
 Ehrie, Michael G., 583-588
 Ehrlich, R.M., *924
 Eichner, Harvey L., 179-182
 Eiseman, B., *924
 Eisenstein, Albert B., 869-875
 Elahi, Dariush, 645-650
 Ellenberg, Max, 418-423
 Ellinger, J., *349
 Ellison, M.G., *385
 Elwood, W.S., *385
 Engelman, Richard M., *634
 England, J., Jr., *374
 Ensinck, John W., *342, *356, *374
 Erlandsen, Stanley L., *339
 Erle, Giuseppe, *154
 Ertel, N.H., *363
 Erwald, R., *990
 Essa, N., *719, *796
 Ewart, T.G., 389-396, 397-404
 Ewing, D.J., 739-742
 Exon, P.D., *859

F

Fábry, P., *482
 Faerman, Isaac, *860, 971-976
 Faibisoff, B., *367
 Fain, J.N., *863-864
 Fajans, S.S., *343, *371
 Fallucca, F., *480
 Falooma, Gerald R., *344, *346, *719, 771-776, *796
 Falorni, A., 172-178

Fanska, R., *337, *344, *922
 Fariss, Bruce L., 189-191
 Farquhar, J.W., *562, *799, *861
 Fasia, A.I.M., *798, *860
 Fearnley, G.R., *481
 Federspil, Giovanni, *154, *560
 Felber, J.P., *370
 Feldman, Jerome M., 21-24, *338, 754-762
 Feldman, Robert, 327-332
 Felig, Philip, *384, *719-720, *797, *859, *992
 Feller, J.H., *922
 Fellers, F.X., *993
 Felts, P., 282-286
 Fernandez-Cruz, Jr., Arturo, *371
 Ferrendelli, J., *337
 Fessard, Cl., *923
 Field, James B., *352
 Fineberg, S. Edwin, *371, 499-504
 Finger, F.E., *349
 Fink, Gloria, 505-511
 Fiser, Robert H., Jr., *371
 FitzGerald, M.G., *562-563, 610-615
 Flatt, J.P., *859
 Fleming, Mary E., *358
 Floyd, J.C., Jr., *343, *371
 Foa, Piero P., *344, *560
 Forgue, Elisabeth, *354
 Forsham, Peter H., *154, 179-182, 192-198, 276-281, *356, *375, *376, 589-596, 763-770, *797, 876-880, *922-923
 Foster, Daniel W., 485-493
 Foster, E., *635
 Fox, Dora, *860, 971-976
 Fox, I.H., *379
 Fracassini, F., 172-178
 Frankel, B.J., *344, *922
 Fraser, T.R., *561
 Freedman, M.H., *924
 Freinkel, Norbert, *342, 771-776
 Frerichs, H., *562
 Freychet, Pierre, *354, *560-561
 Friedman, Gary D., 327-332
 Friedman, Sandor A., *358
 Friesen, H.G., *991
 Friesen, S.R., *798, *922, *991
 Froesch, E.R., *355
 Fujimoto, Wilfred Y., *372, 443-448
 Fujita, Y., *372
 Fulop, M., *561
 Fussgänger, R.D., *155

G

Gabbay, Kenneth H., 460-468
 Gadacz, T., *994

Gagliardino, Juan J., 132-137
 Galbut, D.L., *359
 Galloway, J.A., *352
 Ganda, Om P., *364, *372
 Gander, R., 397-404
 Gannon, M.C., *346, *799
 Ganz, Klaus, *372
 Garber, Alan J., 982-986
 Garbien, K.J.T., *858
 Garcia, Mariano J., 105-111, *635
 Garella, Serafino, *251
 Garty, Jacob, *352
 Gasparo, M. de, *340
 Gauville, C., *924-925
 Gavin, J.R. III, *355
 Geiger, R., 651-656
 Genel, M., *992
 Genuth, S.M., *720, *797
 George, David T., *482, 544-549
 Gerich, John E., *154, *344, *356, *376, *797, *859-860, 876-880, *922-923
 Gerolami, Andre, 896-901
 Gerritsen, G.C., *921, *922
 Gershberg, Herbert, *373
 Geser, C.A., *370
 Ghareeb, A., 112-116
 Charib, H., *798, *990
 Ghoneim, Kh., 112-116
 Giamber, S.R., *796, *989
 Gingerich, Ronald L., *386
 Ginsberg, Henry, 674-678
 Ginsberg, Sandra, *154-155
 Giorgio, M.A., *990
 Gipstein, Robert M., 698-707
 Girard, Jean R., 310-317
 Gleason, Ray E., *253, *350, *372, 616-623, 684-692, *994
 Glick, Seymour M., *358
 Glocer, Leticia, 971-976
 Go, V.L.W., *992-993
 Goetz, Frederick C., *342
 Goff, M.M., *353
 Goldberg, David M., 126-131
 Goldner, Martin, *346
 Goldstein, H. Howard, 306-309, *357
 Goldstein, M.B., *379
 Golman, L., *994
 Gomez, F., *370
 Gonzalez, A., *799
 Goodman, Michael N., *347, 725-731, 881-888
 Goodner, Charles J., 318-326, *356, *374
 Gordon, Phillip, *351, *354
 Gordon, E.E., *373
 Gordon, Tavia, 105-111
 Gordy, Dennis D., *635-636
 Gorelikin, Leo, *345, *798, *860

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336
 Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

AUTHOR INDEX 1974

Gossain, V.V., *923
 Gottlieb, B., *719, *796
 Gottlieb, Marise S., 684-692
 Gotto, A., *372
 Gould, M.K., *154
 Grabner, W., *635
 Grage, T.B., *994
 Grande, F., *863
 Greene, D.A., *357
 Griffey, Michael A., 494-498
 Griffith, B. Herold, *383
 Grinbergs, Marta, *481
 Grodsky, Gerold M., 276-281, *337,
 *340, *344, 763-770, *922
 Grossman, M.I., *561
 Guillemin, Roger, 783-787, 876-880
 Guyda, H.J., *381

H

Hackeng, W.H.L., *863
 Hagen, Thad C., *351
 Hagenfeldt, L., *923
 Hagg, S.A., *347
 Hagler, Louis, 589-596
 Hagroo, Abdul A., 268-275
 Hagura, R., *922
 Hahn, P., *921
 Haim, Anna, *376
 Haist, R.E., 424-432
 Hall, F.F., *990
 Hall, M.R.P., *253
 Halperin, Mitchel L., *154, *370, *379
 Halpern, A., *798, *860
 Han, J., 651-656
 Hansen, Aa. P., *989
 Haour, F., *990-991
 Hare, J.W., *342
 Harrington, John T., *251
 Hatfield, H., *373
 Hauhart, Richard E., *383, 597-604
 Hautecouverture, Michel, 732-738
 Hayashi, K., *923
 Hayden, W.F., *920
 Hayes, J.R., 264-275, *339
 Haymond, M.W., *991
 Hazzard, William R., *351
 Hed, R., *990
 Hedner, P., *923
 Hegre, Orion D., *375
 Heinemann, M., *355
 Hendlar, Rosa, *371, *719-720, *797,
 *992
 Henquin, Jean-Claude, *337, *561,
 933-942
 Henrichs, H.R., 651-656
 Herlong, H. Franklin, *366

Herman, Robert H., 589-596
 Hermreck, A.S., *798, *922, *991
 Herrera, Guillermo, 669-673
 Herrera, M.G., *994
 Hespel, J.-P., *636
 Hetenyi, G., Jr., *863
 Heuser, Gunnar, 698-707
 Heydinger, David K., 579-582
 Hicks, B.H., *343
 Hinsdale, E., *342
 Hinz, Manfred, *373
 Hirata, Y., *991
 Hockaday, T.D.R., *480
 Hochman, H., *858
 Hofeldt, Fred D., 192-198, 589-596
 Hoffman, James R., *342
 Hojnwicki, D., *334
 Hollows, Frederick C., 221-231
 Holm, J., *720, *798
 Honjo, I., *799-800
 Horwitz, D.L., *343, *350
 Hover, B., *340
 Howard, Charles, Jr., *345
 Hsu, T.H., *357
 Hughes, C.R.T., *862
 Hughes, W., *925
 Huise, Mildred, *373
 Humbel, R.E., *355
 Hunter, W.M., *251

I

Iavicoli, M., *480
 Icasas-Cabral, Esperanza A., *368
 Idahl, L.-A., *155
 Ide, Takehiko, 55-60, 412-417
 Iju, Morimasa, 793-795
 Imbembo, A.L., *925
 Ingebretsen, W.R., Jr., *384
 Inoue, Shuji, *374
 Irvine, W.J., 694-697, 708-712
 Isaacson, R., *991
 Isenberg, J.I., *561
 Issekutz, Bela, Jr., 645-650
 Issekutz, Thomas B., 645-650
 Ito, J.I., *991
 Iversen, J., *481, *989
 Iwatsuka, Hisashi, *253, 856-857

J

Jackson, R.L., *350, *374
 Jackson, W.P.U., *155, 257-263,
 264-275
 Jadzinsky, Mauricio N., *860, 971-976
 Jaffer, S.S., *860
 Jahrling, Peter B., *345, *798, *860
 James, Ronald C., 474-479

Janka, Hansuwe, *368, *372
 Jaret, Leonard, 29-40
 Jeanrenaud, B., *561-562
 Jeffay, Henry, *635
 Jéquier, E., *370
 Jen, Phyllis, *354, 565-571
 Jennings, A., *800, *861-862
 Johnsen, K., *350
 Johnson, C.B., *990
 Johnson, David G., *356, *374
 Johnsonbaugh, R., *381
 Jones, Elizabeth M., *383, 597-604
 Jones, M.A., 276-281
 Jonson, Keith M., 221-231
 Joram, A., *923
 Jordan, Jennifer, 694-697
 Juhn, D., *382

K

Kacoyanis, G.P., *989
 Kahn, Charles B., 306-309, *372,
 788-792
 Kahn, Otto, 287-292
 Kajinuma, Hiroshi, 55-60, 412-417
 Kalk, W.J., 257-263, 264-275
 Kalkhoff, R.K., *373, *923
 Kamenetzky, Stephen A., 61-68
 Kamm, D.E., *991
 Kanich, R.E., *921-922
 Kannell, William B., 105-111
 Kanter, Yoram, *374
 Karam, John H., *154, 192-198,
 276-281, *356, *375, *376, 763-770,
 *797, *859-860, 876-880, *922-923
 Karamanos, B.G., *368, *375
 Kardatos, C.G., *375
 Karl, I.E., *991
 Karl, R.C., *337
 Kaselow, D., *482
 Kasemir, H., 651-656
 Kaufmann, Robert L., *375
 Kaung, Hue-Lee, *375
 Kawamori, Ryuzo, *353, 805-815,
 905-912
 Kawasaki, M., *156
 Kazdová, L., *482
 Keller, D., *341
 Keller, P., *155, 257-263, 264-275
 Kellman, J., *376
 Kelly, P.A., *991
 Kemp, Charles B., *359
 Kengis, J., *864
 Kerian, Alice, *352
 Kernevez, J.P., *994
 Kerp, L., 651-656
 Kervran, Alain, 310-317
 Kessler, Gerald, 827-834

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

AUTHOR INDEX 1974

Kessler, J. B., *921-922
 Khalifa, Ahmed, *357
 Khan, Farida, *346, *376, *381
 Kikkawa, Ryuichi, *366
 Kikuchi, Masatoshi, 550-559
 Kim, H.-J., *373
 Kim, H.S., *858
 Kim, S., 605-609
 King, A.J., *992
 King, Katherine C., 816-820
 Kinyon, Louis J., *351
 Kipnis, David M., *341, *636
 Kirby, B.J., *992
 Kirby, L.T., *921
 Kissebah, A.H., *561
 Kitabchi, Abbas E., *355, *387, 536-543
 Klein, Leroy, *366
 Klocke, Robert A., *368
 Kneer, N.M., *347
 Knight, Anthony H., 126-131
 Knight, Michael J., *359
 Knopf, R.F., *343
 Knopp, Robert H., 240-246, *341
 Knowlton, Stephen D., *385
 Koerker, D., *356, *374
 Kohalmi, Diane, 662-668
 Kolodny, Robert C., 306-309
 Konca, L., *358
 Kongtahworn, C., *635
 Konijnendijk, Willem, 203-208
 Korcakova, Lidka, *251
 Kostianovsky, Mery, *376
 Kowarski, A., *340
 Kozak, George P., 405-411
 Kramer, P., *562
 Kramp, R.C., 183-188
 Kraus, Barbara, *368
 Kronfeld, D.S., *334
 Krotkiewski, Marcin, *634
 Kudo, M., *156
 Kuhl, C., 821-826
 Kuhnau, J., Jr., *379
 Kumar, Dinesh, *376, *377, *798, *992
 Kuntzmann, F., *634-635
 Kussman, Michael J., *357
 Kuzuya, Takeshi, 55-60, 412-417
 Kwaan, H.C., *859
 Kwan, Chuk W., *356, 876-880
 Kyner, Joseph L., 684-692
 Kyriakides, G., *359

L

Lacy, Paul E., *359, *377, 517-524, 579-582
 Lacy, W.W., *349, *367
 Lamas, Aldo, 132-137
 Lambert, Andre E., *337, *561, 933-942

Lampe, E.W., II, *992
 Lan, V.V., *635
 Landsberg, L., *341
 Langley, Paul E., *347
 Langlois, M., *797, *859-860
 Lansky, Zena, *634
 Lardy, H.A., *347
 Largis, Elwood E., 51-54
 Laron, Z., *480, *562
 Lasater, J., *990
 Lassman, M.N., *992
 Laube, H., *155
 Lauris, Vilma, *358, *481
 Lavender, S., 247-248
 Lavine, Robert L., *377, 505-511
 Lavis, V.R., *252
 Lawecki, J., *337
 Lawrence, A.M., *349
 Lawrence, John C., Jr., *355
 Lebovitz, H.E., 21-24, *363, *796, *989
 Lecornu, M., *636
 LeCompte, Philip M., 61-68
 Leder, H., *482
 Lee, C.S., *359
 Lefebvre, Pierre J., 81-93, *343
 Legros, F., *368
 Leibel, B.S., 389-396, 397-404
 Lemmens, P., *334
 Leonard, Robert J., 748-753
 Leone, Guy, *348
 Lerner, Roger L., 138-142
 Levacher, C., 889-895
 Levin, Michael L., *251
 Levin, Seymour R., 192-198, *375, 589-596
 Levison, H., *924
 Levitt, B., *353
 Lewis, S.B., *385
 Liban, E., *562
 Liebschutz, D., *994
 Lifton, J., *359
 Like, Arthur A., *358, *720, *798-799
 Liljenquist, J.E., *349, *367
 Lin, T., *992
 Lindall, A.W., *860
 Linder, Cecilio, 143-150
 Littlelike, E.T., *254
 Llorens, Jose M., 132-137
 Lloyd, J.K., *719, *797
 Lober, P.H., *921
 Lockwood, D., *364
 Logothetopoulos, John, *340, 469-473
 Loeb, J.N., *860-861
 Lorenzi, Mara, *356, *376, 876-880
 Loriaux, L., *993
 Loridan, L., *858
 Loten, E.G., *561-562
 Loubatieres, A., *923-924

LoVecchio, Luigi, 293-301
 Lozano, Immaculada, *343
 Lufkin, Edward G., 589-596
 Luft, Rolf, *154, 161-171, 783-787
 Lundbaek, K., *924, *989
 Luyckx, Alfred S., 81-93, *343
 Lynn, W.S., *355

M

Macaron, C., *363
 MacCuish, A.C., 694-697, 708-712, *992
 McDaniel, Huey G., *377
 McDaniel, Michael L., *376, *377, 517-524
 MacDermott, R.P., *562
 Macdonald, Ian, *155
 Mac Donald, M.K., 739-742
 McDonough, M.T., *349
 McFarlane, J.M., *378
 McGarry, J. Denis, 485-493
 McGill, R.J., 247-248
 McIlrath, D.C., *991
 McMillan, Donald E., *378
 McNamara, Patricia M., 105-111
 Mader, M., *355
 Mafei, S., 172-178
 Mager, M., *796, *989
 Magnenat, G., *370
 Maher, Thomas D., *342
 Mahler, Richard J., *378
 Maier, V., *155
 Makhlof, G.M., *860
 Mako, Mary E., *154-155, *350
 Malagelada, J.R., *992-993
 Malaisse, W.J., *378, *481-482
 Malaisse-Lagae, F., *380, *481-482
 Malgieri, J.A., *863-864
 Malins, J.M., *562-563, 610-615, *859
 Mallison, C.N., *861
 Malvaux, P., *561
 Manchester, K.L., *993
 Mandell, F., *993
 Mandelli, V., *333
 Manning, M., *337
 Mantz, F.A., Jr., *922
 Manzano, Francisco M., 405-411
 Marcel, Y.L., *719, *796
 Marco, Jose, *343, *635
 Margolis, S., *340
 Mariani, M.M., *923-924
 Marinan, Barbara, *358
 Marks, Vincent, 902-904
 Marliss, E.B., *370, *379
 Marlow, R.A., *635
 Marquardt, J.L., *993
 Marr, Thomas J., *383
 Martin, Donald B., *348, *385

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

AUTHOR INDEX 1974

Martin, Julio M., 203-208
 Martin, W., *379
 Maruhama, Yoshisuke, *155
 Mason, Edward E., *635-636, *994
 Massaro, R.P., *993
 Massi-Benedetti, F., 172-178
 Massry, Shaul G., *352
 Matin, S., *375
 Matolo, N., *858
 Matschinsky, Franz M., *337, *340, 517-524
 Matsuo, T., *253
 Matsuda, Kiyoshi, 41-50
 Matsuyama, Tatsuo, *344
 Matute, M.L., *923
 Mauer, S.M., *359
 Maurer, S. Michael, 748-753
 Maxwell, E.L., *385
 Maxwell, J.F., *858
 Mayhew, D.A., *337
 Maynard, J., *345
 Mazzaferri, Ernest L., *369
 Mehtalia, Suresh D., *337, *798, *992
 Meinhold, J., *482
 Melissinos, Chyssostomos, *381
 Menibus, C.H. de, *923
 Menzinger, G., *480
 Merimee, Thomas J., *251-252, *371, 499-504
 Metzger, Boyd E., *342, 771-776
 Michael, Alfred F., *359, 748-753
 Mieghem, W. Van, *155
 Migliorini, Renato H., 143-150
 Miller, J., *359
 Miller, J. Philip, 827-834
 Miller, Leona V., *377, *798, *992
 Miller, Max, 61-68, *345, *351, *366
 Miller, P.E.A., *372
 Mitchell, Allen A., 151-153
 Mitchell, J.C., 919-920
 Mitchell, M.L., *800, *862
 Molnar, G.D., *343
 Molnar, I.G., *366, *989
 Mølsted-Pedersen, Lars, 302-305
 Montgomery, J.A., *799
 Moore, Marilyn, *338
 Moore, Robert H., 957-961
 Morain, W.D., *989
 Morgner, D.K., *562
 Morita, Soichiro, *383
 Morrison, A., *719, *796
 Morrison, A.D., *359
 Moser, Charles R., *379
 Mossabhog, N.A., *921
 Motulsky, Arno G., *351
 Moxley, R., *364
 Mozzoli, M., *349
 Mueller, P.S., 743-747

Mullen, Y.S., *366, *989
 Müller, W., *482
 Muller, W.A., 512-516
 Müller-Hess, R., *370
 Munger, Bryce L., *338
 Munichoodappa, Choodappasetty, 835-840
 Munk, P., *924
 Munoz, J.M., *798, *990
 Murphy, James J., *359
 Murrell, L.R., *363
 Murthy, D.Y.N., *350, *374
 Myers, A.R., *993

N

Naeser, P., *155-156
 Nafz, M.A., *384
 Najarian, J.S., *359, *379, *992
 Naji, A., *359
 Nakagawa, Shoichi, *156, 793-795
 Nakayama, Hidetaka, 793-795
 Nanbu, H., *799-800
 Napoli, Elena, 293-301
 Narins, R.G., *993
 Neef, M.A., *333-334, *349
 Neil, G.L., 777-782
 Nelson, Norman C., 199-202
 Nervi, F.O., *799
 Neville, D.M., Jr., *355
 Newton, William T., *359
 Ng, Frank M., *154-950-956
 Nickerson, H., *863
 Nih, Niamud, *353
 Nitzan, Menachem, 771-776
 Nizet, Alphonse H., *343
 Noacco, C., *797, *859-860, *922-923
 Noe, Bryan D., *379
 Noguchi, A., *991
 Norton, L., *924
 Noth, Robert H., *371
 Notkins, A.L., *923
 Nouza, Karel, *251
 Novin, Donald, *636
 Nunn, R., *251
 Nuttall, F.Q., *346, *359, *799
 Nygren, A., *990

O

Ogilvie, James T., 318-326
 Ohkawa, Kiyoshi, *386
 Ohneda, Akira, 41-50
 O'Leary, J.P., *921
 Olefsky, Jerold M., *354, *380, 449-453, 454-459, *562, 565-571, 674-678, *799, *861, *925
 Olsen, Ward A., 716-718

Orci, L., *380, *481-482, *634
 Orsini, G., *333
 Orskov, H., *989
 O'Sullivan, D.J., 440-442
 O'Sullivan, John B., 713-715
 Ouart, J., 25-28
 Owen, O.E., *349, *719, *796
 Owens, Jeanna L., *370
 Ozand, Pinar T., *380
 Ozawa, K., *799-800

P

Pace, B., *350
 Pagliara, Anthony S., *340, 982-986, *991
 Pallotta, Johanna, 433-439
 Palmer, Jerry P., *342, *356, *374
 Palti, Z., *720, *800
 Panzram, G., *482
 Papadimitriou, P.A., *368
 Papenheimer, J.R., *334
 Parenti, M.A., *333
 Parilla, R., 725-731
 Park, Byung M., 616-623
 Parra, A., *156
 Parsons, Jonathan A., *339
 Passa, P., *924-925
 Patel, D.A., *800, *861
 Paulk, S.C., *994
 Paz-Guevara, Aldo T., *357
 Pedersen, Jørgen, 302-305
 Pedrazzoli, S., *560
 Pek, Sumer, *343, *371, 560, 805-815, 905-912
 Pemjps, J.C., *380
 Penhos, J.C., *635
 Pense, G., *482
 Perez, G., 532-535
 Permutt, Marshall Alan, *338, *341, *636
 Perrino, P., *377
 Persico, P.A., *635
 Petersen, B.H., *352
 Petkov, Petko, *482
 Pettersen, Jon Elling, 16-20
 Pfeiffer, Ernst F., *155, *373
 Phillip, J., *635
 Picon, L., 889-895
 Pictet, R., *337, *340
 Pildes, Rosita S., *156, *800, *861, *921
 Pinsker, Richard, *376, *381
 Pisarek, D., *482
 Pissiotis, C.A., *989-990
 Pi-Sunyer, F.X., *365, 605-609, *925
 Pittet, Ph., *370
 Podolsky, Stephen, *365, *381
 Pointer, R.H., *863-864

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-986

AUTHOR INDEX 1974

Polacek, I., 25-28
 Popkave, K., *349
 Porte, Daniel, Jr., 138-142, *341, *356, 624-630, *920
 Portha, B., 889-895
 Posner, Barry I., 209-217, *381, *991
 Poulin, T.L., *989-990
 Pozefsky, T., *364
 Prager, R., *562
 Printen, Kenneth J., *635-636, *994
 Puchulu, Felix E., 132-137
 Punjabi, E., *363
 Pykalisto, Olavi J., *348

Q

Quickel, Kenneth E., Jr., 21-24

R

Rabin, David, *251-252
 Rabinovitch, Alexander, 550-559, *561-562
 Rall, L., *340
 Rall, Theodore W., *252-253
 Ramamurthy, R.S., *800, *861
 Ramahandridona, Georges, 896-901
 Raman, P.G., 788-792
 Ramey, E.R., *380, *635
 Rand, Robert W., 698-707
 Randers, G., *859
 Rapaport, Maurico, 971-976
 Raskin, P., *562
 Rasmussen, Howard K., 716-718
 Rathgeb, I., *719, *796
 Ravazzola, M., *380
 Rayfield, Elliot J., *345, *369, *375, *482, 544-549
 Raymond, L., *381
 Reaven, E.P., *346
 Reaven, Gerald M., *346, *380, 449-453, 454-459, *562, 565-571, 674-678, *799, *861, *925
 Recant, Lillian, *377, 505-511
 Reckard, C.R., *359
 Reddy, William J., *377
 Reeder, D.D., *480
 Regtop, Hubert L., 221-231
 Reichard, G.A., Jr., *349
 Reichle, F.A., *719, *796
 Reid, A., *862
 Rengo, F., 532-535
 Renold, Albert E., *380, 550-559
 Reynertson, Richard H., *348
 Reynolds, C., *343
 Reynolds, W. Ann, 777-782
 Rezek, Milan, *636
 Ribes, G., *923-924

Riff, Emmanuel R., 572-578
 Riff, Kenneth M., 572-578
 Rifkin, Harold, *364
 Robison, G. Alan, *347
 Rodbell, Martin, *252
 Rogers, M., 282-286
 Rogers, P.H., *482
 Roheim, Paul S., *364
 Rojdmark, S., *990
 Romeo, Francesco, 293-301
 Root, Richard K., 9-15
 Rosenbloom, A.L., *378, *382
 Rosenmann, E., *720, *800
 Rosselin, G., 889-895
 Rossini, A.A., *339, *364, *382
 Roth, J., *351, *353, *355
 Roth, Nathan H., 698-707
 Roy, S., *156
 Rubalcava, B., *344
 Rubenstein, A.H., *343, *350, *921, *994
 Rubin, M.S., *156
 Rubinstein, Arthur H., *154-155
 Ruderman, Neil B., *347, 881-888
 Ruiz, J.O., *992
 Ruiz, Jorge, 132-137
 Ruiz, Maximino, 132-137
 Russell, G., *862
 Rutter, W.J., *340

S

Sacca, L., 532-535
 Sahgal, V.K., *156
 Sakai, T., *252
 Sakurai, H., *356
 Salmon, P.R., *861
 Sanders, M.L., *385
 Santiago, Julio, *341, 827-834
 Sasaki, H., *344
 Sato, Munehiko, 41-50
 Sato, Toshio, 41-50
 Saudek, Christopher D., 240-246
 Savage, P.J., *350, *351
 Sawin, C.T., *800
 Scandellari, Cesare, *154, *560
 Schade, D.S., *344, *382, 657-661, *859
 Schafer, Michael E., *383
 Schalch, D.S., *355
 Schauder, P., *562
 Schersten, B., *923
 Scherstén, T., *720, *798
 Schipper, H., 397-404
 Schmeltz, Ralph, *352
 Schmid, Florence, 763-770
 Schnatz, J. David, *351, *363

Schneider, Victor, *356, *797, *859-860, 876-880, *922-923
 Schonfeld, Gustav, 827-834
 Schopman, W., *863
 Schorr, B.A., *860
 Schteingart, D.E., *371
 Schulman, Robert H., *358
 Schulte, W.J., *864
 Schultz, R.B., *156
 Schwartz, Alan L., *252-253
 Schwartz, Robert, 816-820
 Scroggins, K.R., *385
 Scurry, M., *925
 Sedeghi-Nejad, A., *858
 Seeman, Anne, 669-673, *994
 Segovia, Jose, *635
 Seibel, John A., *369, *481
 Seiler, Gwen, 950-956
 Selim, R., 112-116
 Seltzer, Carl C., 327-332
 Seltzer, H.S., *348
 Sener, A., *378
 Senior, Boris, *253, *858
 Setchell, B.P., *334
 Seyer-Hansen, K., *989
 Shabaan, Ahmad A., 902-904
 Sharp, David W., *359
 Sharp, R., 282-286, *800, *861-862
 Sharr, J.F., *925
 Shastri, Narayan V., 977-981
 Shatney, C.H., *994
 Sheldon, J., *251
 Sherman, Abraham A., 218-220
 Shino, Ako, *253, 856-857
 Shroyer, L.A., *384
 Sicolo, N., *560
 Siegelaub, Abraham B., 327-332
 Silbert, C.F., *800, *862
 Simmons, Jeanette J., 669-673
 Simmons, R.L., *992
 Simon, M., *636
 Sinclair-Smith, B.C., *367
 Singh, Harbhajan, *358
 Singh, N., *156
 Siperstein, M.D., *562
 Sirotich, Gino, *154
 Sjöström, Lars, *634
 Sladek, C.D., *925
 Slama, Gerard, 732-738
 Smith, A.W.M., *251
 Smith, L.H., 183-188
 Smith, M.J., *253
 Smith, Phillip H., *348, *356
 Smith, Robert M., 29-40
 Smith, T.M., *350, *382
 Smith, W.O., Jr., *385
 Snyder, N., *925
 Sode, J., *381

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

AUTHOR INDEX 1974

Sodoyez, J.C., *353, *800, *862
 Sodoyez-Goffaux, F.R. *800, *862
 Soeldner, J. Stuart, *253, *350, *372,
 *382, *481, 616-623, 684-692, *800,
 *862, *994
 Solano, Alberto, *368
 Soler, N.G., *562-563, 610-615
 Solomon, S.S., *363, *382
 Sömberg, J.C., *353
 Somers, G., *481-482
 Sonenberg, M., *156
 Sönksen, P.H., *253
 Sosula, Leo, 221-231
 Soufflet, Elizabeth, 310-317
 Spark, Richard, 433-439
 Spaur, W., *381
 Spech, H.-J., *636
 Spellacy, W.N., *253-254
 Spergel, Gabriel, *346, *376, *381
 Sperling, Mark A., *254, *371
 Spooner, Richard J., 126-131
 Spritz, Norton, *358
 Stacpoole, Peter W., 179-182
 Stahl, William M., *634
 Stambaugh, John E., 679-683
 Stanbury, J.B., *859
 Starnes, Willard R., *348
 Starr, J.I., *350, *382, *994
 Steele, R., *719, *796
 Steffes, Michael W., *359, *379,
 748-753, *860
 Steiner, Alton, 869-875
 Steiner, D.F., *354, *921
 Steiner, George, *383
 Steinhilber, S., 651-656
 Steinke, Jurgen, 631-633, *634
 Stenberg, Jesper, *634
 Stephens, John H., *345
 Still, M., *376
 Stillings, S., *340
 Stilmant, Magda M., *251
 Stinson, C., *990
 Stout, R.W., 624-630
 Stowers, J.M., *862
 Strack, Inge, 860-875
 Strigl, P., *635
 Strope, G.L., *991
 Suda, N., *156
 Sullivan, Lars, *634
 Sultz, Harry A., *351
 Summerskill, W.H.J., *992-993
 Sun, A.M., 424-432
 Sutherland, David E.R., *359, *379,
 748-753
 Sutherland, H.W., *862
 Suwanwela, N., *859
 Suzuki, T., *373
 Suzuki, Z., *253

Swain, C.T., *862
 Swander, Anna, *367
 Swartz, Frank J., 583-588
 Swenson, Richard P., *384
 Swislocki, N.I., *156
 Szabo, Andrew J., *342, *353
 Szabo, Olga, *342

T

Taft, H.P., *154
 Taft, Pincus, 943-949, 950-956
 Taketomi, Shigehisa, 856-857
 Tamburrano, G., *480
 Tan, Meng H., *481, 512-516
 Tannenbaum, H., *561
 Tantillo, J.J., 276-281, *376
 Taylor, C.I., *343
 Taylor, Keith W., 631-633
 Taylor, W.F., *343
 Tchobroutsky, Georges, 732-738
 Teague, Jeanette, *372
 Teitelbaum, A., *720, *800
 Terris, S., *354
 Thomas, C.Y., IV, *798, *991
 Thomas, D., *994
 Thompson, A.G., *922
 Thompson, B.W., *920
 Thompson, J.C., *480
 Thompson, W. Leigh, *254
 Thorell, Jan I., *254
 Thulin, T., *923
 Thurston, Jean Holowach, *383, 597-604
 Tildon, J. Ryson, *380
 Tilsner, V., *379
 Titlbach, Milan, *251
 Tobin, J.D., *341, *364
 Toews, C.J., 725-731
 Tominaga, M., *991
 Tomita, Tatsuo, 517-524
 Touitou, D., *634-635
 Tountas, C.D., *368
 Tourtellotte, C.D., *482
 Toussaint, G.P.M., *922
 Trafford, J.A.P., *251
 Traisman, Howard S., *383
 Tron, Ph., *923
 Tsushima, T., *991
 Tucci, J.R., *992
 Tucker, Dale C., 679-683
 Tulloch, B.R., *561
 Turner, Desmond S., 902-904
 Turner, R.C., *480
 Tyler, Jean M., *383

U

Unger, G.F., *864

Unger, Roger H., *356, *372, *380,
 771-776, *862-863
 Urbaniak, S.J., 708-712

V

Vague, Philippe, 896-901
 Vaishnava, Hari, 268-275
 Valdivieso, V.D., *799
 Vallance-Owen, J., *480
 Valverde, Isabel, *343, *635
 Van Den Brande, J.L., *863
 VanderWeele, Dennis A., *636
 Van Obberghen, E., *339, *481-482
 Van Orden, Lucas, S., *339
 Van Son, Allene R., *351
 Varandani, Partab T., 117-125, 232-239,
 *384
 Varco, R.L., *921
 Varma, S., *863
 Velasco, C.A., *858
 Veneziale, Carlo M., *384
 Verhaegen, H., *334
 Verma, Narendra P.S., 268-275
 Vij, S.K., *343
 Villanueva, Maria L., *343, *635
 Vinicor, Frank, 662-668
 Vinik, A.I., 257-263, 264-275
 Visser, H.K.A., *863
 Volk, Bruno W., *381, *636
 Vongsavanhong, S., *636
 Voyles, N., *377
 Vrakko, Rudolf, 94-104, *863
 Vrána, A., *482
 Vranic, Mladen, *353, *383, 805-815
 905-912

W

Wagle, S.R., *384
 Wagner, W.G., *989-990
 Wagner, William, 287-292
 Wahba, N., 112-116
 Wahren, J., *719-720, *797
 Wainer, R.A., *254
 Wajchenberg, B.L., *798, *860
 Wall, David A., *383
 Wallin, J.D., *385
 Wallis, M., *334
 Walsh, C.H., 440-442
 Walsh, J.H., *561
 Wannemacher, Robert W., Jr., 544-549
 Ward, W.F., *863-864
 Warin, A.P., *861
 Warren, John, *384
 Warshaw, A.L., *925
 Watkins, D.T., *338
 Way, L.W., *994

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80
 February, 81-160
 March, 161-256
 April, 257-336

Supplement 1, 337-388
 May, 389-484
 June, 485-564
 July, 565-644

August, 645-724
 September, 725-804
 October, 805-868
 November, 869-932
 December, 933-996

AUTHOR INDEX 1974

Weigand, D.A., *366
 Weiland, L.H., *991
 Weinsier, Roland L., 669-673, *994
 Weir, Gordon C., *385
 Weisberg, J.S., *993
 Weiser, P.C., *863
 Weiss, J.L., 743-747
 Weiss, Steven, *358
 Welch, N.N., *635
 Welker, Charles, 943-949
 Wellmann, Klaus F., *381, *636
 Wentworth, S.M., *352
 Wernze, H., *636
 Weser, E., *864
 West, Kelly M., *385, 841-855
 Westbie, D.K., *385
 Wester, P.O., *923
 Whalen, G.E., *864
 Whayne, T.F., *385
 White, Priscilla, *357
 Whitney, John E., 494-498
 Wiechel, K.-L., *990
 Wiernik, P.H., *254

Wiester, P.B., *863-864
 Wilkinson, Jack Sidney, *385
 Williams, David N., 126-131
 Williams, Robert H., *252, *339, *372,
 443-448
 Williamson, John R., *386
 Wilson, R.B., *334
 Winegrad, A.I., *357
 Wise, J.K., *992
 Witzel, D.A., *254
 Wollesen, F., *254
 Wollmer, A., *560-561
 Wolstenholme, J.T., *994
 Wong, E.T., *860
 Woods, J.E., *858
 Woods, Stephen C., *341, *356
 Woodward, E.R., *921
 Wrenshall, G.A., *353
 Wright, Peter H., *386
 Wu, W.C., *864

Y
 Yamagata, Shioichi, 41-50

Yamaguchi, Kiyoko, 816-820
 Yamaoka, Y., *799-800
 Yeast, J., *350
 Yodaiken, Ralph E., *386
 Young, E.A., *864
 Young, J.B., *341
 Yu, Stephen S., *387

Z
 Zaccaria, Marco, *154
 Zapf, J., *355
 Zawalich, W.S., *337
 Zelson, C., *858
 Zfass, A.M., *860
 Zic, Zeljiko, 788-792
 Ziegler, M.M., *359
 Zieve, L., *990
 Zimmerman, C., *358
 Zimmet, Paul Z., 943-949, 950-956
 Zingg, W., 389-396, 397-404
 Zucker, Peter, *340

DIABETES: VOLUME 23 (1974) PAGE NUMBERS BY ISSUE

January, 1-80	Supplement 1, 337-388	August, 645-724
February, 81-160	May, 389-484	September, 725-804
March, 161-256	June, 485-564	October, 805-868
April, 257-336	July, 565-644	November, 869-932
		December, 933-996



American Diabetes Association, Inc.
1 West 48th Street
New York, N.Y. 10020

